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Abstract
Polymorphous low grade adenocarcinoma (PLGA) is the second most common
malignant salivary gland tumour of the minor salivary glands. Human tissue kallikreins
(KLKs) are a family of highly conserved serine proteases expressed by various tissues
throughout the body. KLKs have become powerful tumour markers for the diagnosis of the
cancer patient (e.g. PSA (KLK3)). The literature demonstrates a link between KLKs and
salivary gland neoplasms. The purpose of this study is to determine levels of KLK mRNA
in tissue samples of formalin fixed paraffin embedded polymorphous low grade
adenocarcinoma (PLGA). Secondly, we wish to determine if KLK expression is limited to
tumour cells alone.
Nineteen cases of PLGA were reviewed (1987-2013). A diagnosis of PLGA was
confirmed, demographic data was collected, and formalin fixed paraffin-embedded PLGA
and normal salivary gland tissue samples were obtained. RNA isolation was achieved,
followed by conversion to complementary DNA via reverse transcription. Synthesized
DNA primers were added to target kallikrein DNA and through PCR, the quantitative level
of expression of KLKs 1-15 was recorded. Samples exhibiting high and low KLK
expression were selected for immunohistochemistry staining, using a standard protocol.
Results from PCR data reveals statistically significant increase in the mean KLK
mRNA expression for KLK1, KLK4, KLK10, KLK12 and KLK15 in PLGA tissue
samples, as compared with normal salivary gland tissue (Mann Whitney U test, p<0.05).
Immunohistochemistry results demonstrate tumour specific staining. Notably, all samples
demonstrating relatively higher KLK mRNA expression showed equivalent or increased
staining grade scores relative to the low KLK mRNA expression samples, with respect to
a specific KLK.
In tissue samples of polymorphous low grade adenocarcinoma there is an increase
of KLK1, KLK4, KLK10, KLK12 and KLK15 mRNA relative to normal salivary gland
tissue. Furthermore, the tumour cells stain positively and specifically for kallikreins.
Keywords: Salivary gland neoplasm, polymorphous low-grade adenocarcinoma, human
tissue kallikreins, RT-PCR, immunohistochemistry, biomarkers
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Chapter 1
1.0 Introduction
1.1 Salivary Gland Neoplasms
Salivary gland tumours comprise 2-6.5% of all head and neck malignancies and have a
global incidence of approximately 1-6.5 cases per 100,000 persons annually[1, 2]. These tumours
are most commonly found in the parotid gland, but may also occur in the other major salivary
gland tissue, the submandibular and sublingual glands, as well as the minor salivary glands[2, 3].
The minor salivary glands are widely distributed along the upper aerodigestive tract, including the
lips, gingiva, buccal mucosa, palate, tongue, oropharynx, paranasal sinuses, and the
parapharyngeal space[4].
Although the parotid comprises 64-80% of all salivary gland neoplasia cases, only about
15-32% of these tumours are malignant[2, 5]. The most common benign salivary gland tumour of
the parotid gland is pleomorphic adenoma (PA), whereas the most common malignancy is
mucoepidermoid carcinoma (MEC)[1, 2, 5]. Submandibular glands account for about 8-11% of
salivary gland tumours; however, the rate of malignancy is substantially higher, ranging from 3745%[2]. Still, PA remains the most common benign entity, and adenoid cystic carcinoma (ACC)
is the most common malignancy, found in the submandibular glands[2]. Tumours in the sublingual
gland are rare, occurring <1%, but the gross majority are malignancies[2]. Minor salivary glands
comprise 9-23% of salivary gland tumours[2]. They are more common to be malignant, with MEC
being the most common malignant tumour of the minor salivary glands[2, 5].
1.1.1 Polymorphous Low-Grade Adenocarcinoma
Polymorphous low-grade adenocarcinoma (PLGA) was first described in 1983 by
Freedman and Lumerman, and Batsakis et al. as “lobular carcinoma” and “terminal duct
carcinoma” for its similarities to lobular carcinoma of the breast[6-9]. In 1984, the term
“polymorphous low-grade adenocarcinoma” was suggested by Evans and Batsakis, and,
subsequently, it was recognized as its own entity by the World Health Organization (WHO) in
1990[9-12]. Previous to this, it was considered under the umbrella of pleomorphic adenoma,
adenocarcinoma NOS, or ACC[2, 13]. By definition, PLGA is a “malignant epithelial tumour
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characterized by cellular uniformity, morphologic diversity, an infiltrative growth pattern, and low
metastatic potential”[3]. PLGA is a diagnostic challenge for pathologist, overlapping in histologic
characteristics with other salivary gland neoplasms[14].
1.1.1.1 Epidemiology, demographics
PLGA is the second most common malignant salivary gland tumour of the minor glands
and the third most common salivary gland tumour found in the oral cavity[14, 15]. It comprises 711% of all tumours in the minor salivary glands, and 19-26% of all malignancies of the minor
salivary glands[9]. PLGA is not limited to minor salivary glands, but may occur in major salivary
glands or from an existing pleomorphic adenoma; however, in both instances this is rare[8, 9, 11].
In a 2015 retrospective study, the incidence of PLGA was noted to be 0.051 per 100000 persons
annually[11]. In their 2013 epidemiologic study, de Araujo et al. noted a significant increase in
the fraction of PLGA cases reported in the literature since 2007, but did suggest this was secondary
to improved diagnostic accuracy by pathologists[16]. PLGA is most commonly found in the
Caucasian population; however, some publications have reported higher incidences amongst Asian
and African populations [11, 16, 17]. Two retrospective studies out of Northeast and Eastern China
documented a lower incidence of PLGA in these regions, than that noted globally[4, 18]. PLGA
has a female predilection, with a female-to-male ration of 2.15:1[11, 19]. PLGA is most frequent
in the 6th and 7th decades; the age of presentation peaks during the 6th decade[16, 20]. Cases in the
literature vary from the 2nd to 10th decades of life, with the mean age at time of diagnosis being
61.3 years of age[4, 11].
1.1.1.2 Clinical Features
The clinical presentation of PLGA is non-specific and patients may or may not have
symptoms[10, 13, 21]. Most commonly, this tumour presents as a firm, non-tender swelling of the
palate, buccal or lip mucosa[21]. The lesion may exhibit pain, and infrequently, paresthesia[13,
20]. Patients, on average, have symptoms for 27 months prior to diagnosis. Usually the mass lies
within the submucosal plane, with intact and normal surface epithelium[20]. However, bleeding,
ulcerations and telangectasias have been reported[21]. Furthermore, Chi and Neville recently
described a rough stippled overlying mucosa feature, which was significantly found more often in
PLGA tumours versus non-PLGA tumours[21].
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The most common location to develop PLGA is on the palate, particularly at the junction
of the hard and soft palate, where many minor salivary glands reside[11, 13, 16]. PLGA is also
regularly found on the lips, as well as the buccal mucosa. Other intra-oral sites include: retromolar
trigone, tongue, mandible, floor of mouth, and gingiva[10, 22]. Although rare, PLGA may occur
in the major salivary glands; Sun et al.’s review of sublingual gland pathology in 2010 noted PLGA
comprised 4.76% of tumours of the sublingual gland [23]. Even more rarely, PLGA may be found
in extra-oral sites, including: the maxillary sinus, paranasal sinuses, lacrimal glands, orbit, ear,
oropharynx/base of tongue, nasopharynx, larynx, uvula, breast and mammary gland, vulva, vagina,
and skin[17, 24, 25]. Lesions have been found in the lungs as metastases, but also as primary
lesions[15].
PLGA is usually a slow growing tumour, but tumour size can vary from smaller to larger
diameters, depending on location. The average tumour size at the time of presentation is 2.1 cm
+/- 1.3 cm[11, 14, 16]. PLGA may be locally invasive, for example, palatal lesions will eventually
invade the adjacent maxillary bone and sinuses[19]. Regional lymph node metastasis has been
reported as high as 29%, but there is rarely hematogenous spread[26-28]. However, distant
metastasis have reportedly been found in the lung and abdomen[29]. In their retrospective
epidemiologic study, Patel et al. found a distant metastasis rate of 4.3%[11].
1.1.1.3 Imaging Features
PLGA exhibits variable radiographic characteristics; features are generally consistent with
a slow growing, but aggressive tumour[8]. In a radiology journal, Potluri et al. presented a PLGA
case with significant imaging findings; plain film investigations noted loss of maxillary bone and
lack of sinus floor visualization, whereas computed tomography showed irregular cortical density,
thinning of cortical plates, and mass effect with maxillary bowing and bony perforations[8]. Soft
tissue findings on imaging noted hypervascularity and irregular contrast enhancement[8].
1.1.1.4 Histopathology
PLGA is defined histologically as a well-circumscribed, non-encapsulated lesion with
infiltrative borders[6, 11, 29, 30]. As the name “polymorphous” would suggest, this tumour
demonstrates substantial histologic heterogeneity. Multiple growth patterns have been seen,
including: solid, cribriform, trabecular, ductotubular, fascicular, papillary, glandular, cord-like,
3

and lobular[10, 14, 16, 20]. Importantly, more than one pattern may be visualized in the same
tumour[9]. Furthermore, certain growth patterns, such as papillary, have been associated with more
aggressive clinical behaviour, and higher rates of metastasis[26, 31].
Concentric growth patterns are often exhibited, with streaming columns of single-filed
tumour cells, forming “whorls”, which appear targetoid in nature[12, 13]. The surface epithelium
is usually not violated by tumour cells, and infiltrating nests or islands are less common, rather the
tumour cells exhibit a “pushing” type of invasion[6, 13]. The tumour cells have been shown to
invade salivary glands, muscle, connective tissue and bone; however, true skeletal muscle invasion
is rare[6, 9].
While, histomorphologically heterogeneous, PLGA displays nuclear homogeneity[11].
Nuclei are round, open-faced with dense and scattered nucleoli[13]. They demonstrate a classic
“salt and pepper” nuclear form, with optically clear chromatin[8, 10, 14]. PLGA tumour cells
contain scant to moderate cytoplasm, which may be eosinophilic, amphophilic, and infrequently
contain oncocytes and mucin cells[6, 9, 16]. Langerhans cells have been seen in greater density
with PLGA than other salivary gland malignancies, but not to a statistically significant level[32].
Again, as its title would suggest, PLGA demonstrates “low-grade” pathologic features. Cell
necrosis and hemorrhage are infrequently encountered and mitosis are scant, if present[6, 10, 30,
31]. Peri-neural and intra-neural invasion is seen; however, it does not correlate with more
aggressive clinical behaviour[9, 16, 33]. Moreover, these tumours may display prominent
vascularity, with perivascular invasion occasionally evident[16]. According to Ki-67 staining for
proliferation indices of tumours, PLGA exhibits a relatively lower mean proliferation index
(<6.4%), signifying a more indolent behaviour[25].
In their epidemiologic study, Patel et al. revealed 37.2% of PLGA tumours were welldifferentiated/Grade I, and the remaining 62.8% of cases were moderately differentiated/Grade
II[11]. Rare cases of histologic transformation from low-grade to high-grade have been
reported[15, 26, 29]. This de-differentiation has correlated to more aggressive clinical
behaviour[26].
The diagnostic challenge PLGA poses is its morphologic resemblance and overlap with
PA and ACC under the microscope[14, 34]. Specifically, all three of these neoplasms exhibit
cribriform and tubular growth patterns[26]. Given the therapeutic and prognostic differences
between these entities, it can be a significant pitfall to misdiagnose[9]. PA is composed of
4

proliferating epithelial, stromal, and myoepithelial cells which do not demonstrate the infiltrative
pattern seen with PLGA; however, this is not always apparent, particularly in smaller biopsy
specimens[22]. Myxochondroid and chondroid regions are seen commonly in PA, which can aid
in differentiating from PLGA[22]. ACC is more common in major salivary glands, where PLGA
is uncharacteristically found, so this is often useful in distinguishing between the two tumours[9].
Overlapping microscopic features seen with ACC and PLGA include: diffusely invasive borders,
solid and cribriform growth patterns, and perineural invasion[35]. ACC characteristics that set it
apart from PLGA are smaller cell size with less cytoplasm, hyperchromatic nuclei, coarser nuclear
chromatin, and a higher nuclear-to-cytoplasmic ratio[6].
1.1.1.5 Diagnosis
The diagnostic work up for PLGA consists of a thorough history and physical examination,
followed by appropriate diagnostic imaging. Many diagnostic modalities, such as sialography,
radionucleotide scanning, and ultrasonography primarily have a role in pathology of the major
glands[5]. Computed tomography (CT) and magnetic resonance imaging (MRI) are the favoured
imaging modalities when investigating minor salivary glands[5]. Despite information gained from
imaging studies, neoplastic growths of the salivary glands require histological tissue diagnosis.
Fine-needle aspiration biopsy (FNAB) has a role in the diagnosis of major salivary gland
pathologies; however, in minor salivary gland pathology it has little to no value[5]. The hallmark
of diagnosis for PLGA remains adequate open tissue biopsy.
1.1.1.6 Treatment and Prognosis
The treatment of choice for PLGA is surgery, with or without adjuvant radiotherapy[5, 11].
Surgery usually consists of wide local excision, with 1cm margins, or resection to the closest
anatomic barrier[5]. In most cases, this will achieve local control of disease[15]. Depending on
tumour size, reconstruction may be necessitated[30]. Neck dissection is generally not warranted
in N0 disease; however, some advocate that if the primary site of PLGA is the base of tongue
(BOT), it should be more seriously considered[17]. Others suggest therapeutic neck dissections
should be limited to patients with clinical and radiographic evidence of positive cervical
lymphadenopathy[19]. Furthermore, Pogodziski et al. and Gonzalez-Garcia et al. have
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recommended no neck dissection unless a major resection and reconstruction has been
planned[11].
The role of radiotherapy for the treatment of PLGA remains uncertain[1, 5, 11, 30].
Adjuvant radiotherapy is considered in the setting of positive surgical margins; typical dosages are
66Gy in 33 fractions for residual microscopic disease or 70Gy in 35 fractions for gross residual
disease[30]. Furthermore, radiation may be considered as a primary treatment when patients are
not suitable for surgery, when complete resection is not possible, or if the tumour is in close
proximity to vital structures (e.g. parotid gland PLGA about the facial nerve)[17]. A cohort study
by Castle et al. and a case series by Kimple et al. both demonstrated that post-operative
radiotherapy had no significant change in patient outcomes[6, 10]. In the context of negative
surgical margins, peri-neural involvement seen in PLGA does not warrant adjuvant radiotherapy,
as it does not affect prognosis, and may be monitored[30]. Patel et al. reported that in all cases
treated from 2001-2011, 77.9% had surgery alone, 2.6% had radiation alone, and 19.5% were
treated with both[11]. Adjuvant chemotherapy has seldom been given, and requires further
investigation as to its usefulness in the treatment of PLGA.
Staging of PLGA utilizes the American Joint Committee on Cancer (AJCC), Tumor,
Nodes, Metastases (TNM) system. Patel et al. were able to obtain staging for 319/460 PLGA cases
reviewed in their study; the tumours comprised the following stages: Stage I: 46.7%, Stage II:
17.6%, Stage III: 5.6%, and Stage IV: 11.9%[11]. Further classification using TNM was also
reported. Tumour status, T1: 48%, T2: 20.1%, T3: 4.4%, T4: 10.0% and Tx: 17.6%, node status,
N0:88.4%, N1:3.4%, N2: 1.6%, and Nx:6.6%, and metastases status, M0: 93.1%, M1: 1.6%, and
Mx: 5.3%[11].
Recurrence rates for PLGA vary in the literature, but have been reportedly as high as
33%[11, 36]. Other documented ranges for local recurrence have suggested 9-17%[2, 3, 21].
Recurrences of PLGA have been found in the context of negative surgical margins[20, 24]. It has
also been reported that females are more likely to experience recurrent disease[6]. Late recurrences
are not uncommon, with reports of recurrent PLGA arising anywhere between 1 and 24 years[10,
30]. The average time to present with recurrence of disease is 7.2 years[6, 17]. In their case series,
Kimple et al. stated 50% of recurrences happened by 35 months, and they also went on to note of
the recurrent PLGA cases studied, 54% demonstrated local recurrences, 32% were nodal, and 8%
were distant[10]. Rates of recurrence with surgical resection alone, compared to surgical resection
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with adjuvant radiotherapy have not demonstrated any significant difference[6, 10].
Histologically, recurrent disease appears more aggressive, with evidence of papillary
histomorphology, increased mitotic figures, and overall “intermediate-grade adenocarcinoma”[11,
17]. Interestingly, peri-neural invasion has not been linked to increase rates of recurrence in
PLGA[11]. The potential for delayed recurrence, and recurrent nodal disease, warrants prolonged
clinical follow up; recommendations for at least 15 years of follow up have been suggested[20,
31].
Overall, the prognosis for PLGA is excellent[13, 21]. The 5 and 10-year disease specific
survival (DSS) has been reported as 98.6% and 96.4%[11]. Based on treatment modality, 10-year
DSS survival notes 98% for surgery alone, 90.9% for surgery, with adjuvant radiotherapy, and
75% for radiotherapy alone[11].
1.1.1.7 PLGA variant, Cribriform adenocarcinoma of the tongue and minor salivary glands
Recently, a variant of PLGA has been noted in the literature, thought to differ in clinical
location, behaviour and histopathology[12]. Termed “Cribriform Adenocarcinoma of the Tongue
and Minor Salivary Glands” (CATMSG), it is currently regarded as a “provisional entity” by the
WHO[33]. Originally, Michal et al. described this tumour as Cribriform Adenocarcinoma of the
Tongue in 1999; however, with more cases reported, the term has now expanded to include the
minor salivary glands[26]. Presently, there are 41 well-documented CATMSG cases in the
literature, but it remains controversial whether CATMSG and PLGA remain separated entities or
whether they are variants of one tumour spectrum[26, 37].
CATMSG occurs primarily in adults, with one adolescent case report by Takhar et al[12,
37]. Unlike PLGA, CATMSG shows no gender predilection[37]. Furthermore, CATMSG
demonstrates a more aggressive clinical behaviour, having higher rates of local metastatic spread
(61.2%)[12, 33]. Michal et al. postulate that if CATMSG was considered a separate entity, the rate
of PLGA metastasis to regional lymph nodes would be significantly lower[33]. Distant metastases
have not been reported to date[38]. Although more patient lymph node metastases at the time of
presentation, the tumour remains indolent overall, with a favourable prognosis[33].
Histologically, CATMSG shares characteristics of cribriform, microcribriform, and solid
patterns with PLGA; however, it can exhibit clefts and tumour nests resulting in a glomeruloid
appearance[33, 38]. Moreover, the nuclei overlap, are pale, optically clear, with a ground glass
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appearance, making this tumour variant quite histologically similar to papillary thyroid
carcinoma[38]. Rarely, psamomma bodies may be seen[33]. Importantly, these tumours stain
negatively for thyroglobin and TTF-1[33, 38]. The immunohistochemical profile of CATMSG has
otherwise been variable; positive staining has been noted in cytokeratin markers (AE1-3, CAM5.2,
CK7, CK8, CK18), S-100, SMA, calponin, and vimentin. C-kit, p16, cyclin D1, p53, and CK19
have been inconsistent. Lastly, the Ki-67 index has usually been low[33].
1.1.1.8 Biomarkers associated with PLGA
In an effort to improve diagnostic accuracy in salivary gland pathology, many groups have
examined the immunohistochemical profile of PLGA. The summary of biomarkers studied to date
are presented in Table 1.1.1.8.1.
1.1.1.8.1 Ki-67
Ki-67 is a cell cycle-associated antigen which is useful as a biomarker for cell proliferation,
and is therefore, thought to have use as a prognostic indicator in salivary gland malignancies[35,
39]. Ki-67 is only expressed by proliferating cells, and has its peak expression in M phase of the
cell cycle[39]. The Ki-67 index for PLGA is usually <6.4%, with mean values 1.6%-2.4%[3, 37].
In comparison to other malignant salivary gland tumours, Skalova et al. and Vargas et al. reported
PLGA had a significantly lower Ki-67 index than ACC[14, 30]. Beltran et al. also demonstrated a
lower Ki-67 index in PLGA versus ACC; however, this was only “suggestive statistical
significance”[35]. Other groups have noted no significant difference in Ki-67 index between ACC
and PLGA and/or an increased index in PLGA[7, 29, 35]. Higher Ki-67 indices have been seen
with de-differentiated PLGA tumours, and therefore, a ki-67expression analysis may be a useful
tool in identifying this high-grade variant of PLGA[29]. In their 2011 study, Falchete do Prado et
al. examined Ki-67 and fatty acid synthase expression in salivary gland tumours, noting greatest
fatty acid synthase expression in PA and higher Ki-67 index in salivary gland malignancies[39].
MEC showed the highest Ki-67 index, followed by ACC and PLGA; there was no correlation
between fatty acid synthase expression and Ki-67 index[39].
1.1.1.8.2 C-kit (CD117)
C-kit is a proto-oncogene that encodes a transmembrane receptor tyrosine kinase and is
shown to be overexpressed in ACC[3, 35]. In their clinicopathologic study, Schwarz et al. cited
their most remarkable finding was that c-kit expression is primarily absent in PLGA, when
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compared to ACC[7]. Beltran et al. found PLGA had significantly weaker staining for c-kit in
PLGA versus ACC[35]. Moreover, Rooper et al. presented studies demonstrating diffuse positive
c-kit staining in ACC and c-kit negative staining in PLGA; however, they cited other studies noting
no significant difference between the two malignancies[14].
1.1.1.8.3 p63+/p40Recently, a p63+/p40- immunohistochemical staining panel has been argued as a valuable
tool for diagnosing PLGA. The immunohistochemical marker p63 is normally expressed in the
basal layer of stratified epithelium, myoepithelial cells, and the malignancies that proliferate from
these cells[14]. It’s isotype, p40 is a more specific marker of basal stratified epithelial and
myoepithelial differentiation[14]. To date, p63 has not shown diagnostic use for PLGA, as despite
lack of myoepithelial proliferation in this tumour, it stains diffusely positive for p63; however,
Rooper et al. demonstrated that PLGA stained negatively for the more specific p40 isotype[14].
They concluded that the p63+/p40- phenotype was 100% sensitive and 93% specific for PLGA,
showing diagnostic promise[14].
1.1.1.8.4 p53
p53 is a tumour suppressor protein encoding for a nuclear phosphoprotein, controlling cell
proliferation[40]. PLGA has shown variable p53 staining in the literature as well[9]. Some studies
demonstrate little p53 staining in PLGA, whereas other groups report PLGA shows the highest
expression of p53 out of all salivary gland neoplasms[34].
1.1.1.8.5 S-100
The S-100 protein family is a group of low molecular weight proteins, with calcium binding
sites and are expressed by a number of cell types[41]. Furthermore, these proteins have been
implicated in inflammatory process regulation, as well as the development of metastasis in several
cancers[41]. S-100 protein stains have been well-examined in salivary gland neoplasia[9]. The
majority of PLGA are S-100 positive, demonstrating diffuse staining[6, 42]. In contrast, ACC and
adenocarcinoma NOS both show weaker S-100 protein staining; however, ACC staining may be
variable[9, 42].
1.1.1.8.5.1 Mammaglobin and S-100 co-expression
To improve the diagnostic value of S-100 in salivary gland neoplasms, Patel et al. studied
its co-expression with mammaglobin, a glycoprotein and biomarker used in breast cancer[43].
They concluded that 100% of PLGA cases stained positive for mammaglobin, and 93% of PLGA
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cases stained positive for S-100[42]. Ultimately, 60% of PLGA cases met the staining criteria for
co-expression of S-100 and mammaglobin, whereas only 13.3% cases of ACC met such
criteria[42].
1.1.1.8.6 CD43
CD43 is a transmembrane surface protein, normally expressed in T lymphocytes, natural
killer cells, and myeloid cells[44]. Weak expression of CD43 has been found in epithelial cells,
synovial cells, fibroblasts and chondrocytes[44]. CD43 has been found to be expressed more
strongly in ACC when compared to PLGA[13, 21].
1.1.1.8.7 Osteopontin (OPN), CD44, integrin avb3
OPN is an acidic phosphoglycoprotein, which interacts with two ligands, cell receptors
CD44 and integrin avb3, and is expressed in various tumours[45]. Increased expression of OPN is
thought to be involved with malignant tumour invasion and metastasis[45]. Fok et al. studied the
expression of osteopontin, as well as it’s ligands in salivary gland tumours, concluding that PLGA
and ACC demonstrate increased OPN expression compared to benign salivary gland tumours and
normal salivary gland tissue (NSGT)[45]. Furthermore, CD44 expression was reduced in PLGA,
which they postulated could suggest a less aggressive tumour behaviour, as CD44 interacts with
OPN to promote metastasis[45]. Integrin avb3 showed scattered staining in PLGA[45].
1.1.1.8.8 Cytokeratins, Vimentin
Cytokeratins are keratin-containing intermediate filaments, which are expressed in
epithelial tissue and may be divided into low and high molecular weight keratins[46]. Cytokeratins
have shown positive staining in PLGA, specifically de Araujo et al. noted CK8 and CK18 to have
increase expression in PLGA[47].
Vimentin is an intermediate filament protein that is expressed by mesenchymal cells[47].
PLGA has demonstrated positive vimentin staining in various studies, and in contrast, ACC shows
weaker staining[30]. Darling et al. reviewed the literature for the immunohistochemistry staining
profile of PLGA, and concluded that vimentin was the only immunohistochemical marker to
reliably differentiate PLGA from ACC[9].
1.1.1.8.9 Carcinoembryonic antigen (CEA)
CEA is a glycoprotein which functions in cell adhesion. CEA has demonstrated expression
in ACC; however, the CEA expression profile has varied with PLGA[9, 30]. Several groups have
shown PLGA stains negatively for CEA, whereas other groups have reported some staining
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variability, thus CEA is not uniformly negative in PLGA and has decreased diagnostic value[9,
29].
1.1.1.8.10 Smooth muscle actin (SMA), muscle specific actin (MSA), galactin-3, cyclin D1,
glial fibrillary acid protein (GFAP), epithelial membrane antigen (EMA)
Other biomarkers have been less reliable in differentiating between salivary gland tumours.
Multiple studies have shown that ACC demonstrate increase expression of smooth muscle actin
(SMA), and increased nuclear expression of galectin-3 and cyclin D1, as compared to PLGA[10,
21, 30]. GFAP staining has been reported as both negative and positive in PLGA; its expression is
relatively higher in PA, whereas ACC’s expression of GFAP is unknown[9, 14]. EMA stains
positive in both ACC and PLGA[9]. MSA stains moderately positive in ACC; however, in PLGA
the stain is negative to weak[9].
1.1.1.8.11 Maspin and Mini-chromosome maintenance protein (MCM2)
Maspin is a mammary serine protease inhibitor, that functions to prevent apoptosis and
decrease cell invasion, and may have a role in preventing angiogenesis[48]. MCM2’s are mini
chromosome maintenance proteins, which are paramount for DNA replication and therefore, have
use as markers for cell proliferation[48]. In 2011, Ghazy et al. studied the expression of maspin
and MCM2 in salivary gland tumours, and specifically wanted to determine if their expression
correlated to lymph node metastasis[48]. Salivary gland tumours, including PLGA and ACC,
stained positively for both maspin and MCM2 to a variably degree, but ACC showed a higher
proliferation profile versus PLGA. There was no significant correlation between maspin and
MCM2 expression and regional metastatic disease[48].
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Table 1.1.1.8.1. Biomarkers studied in PLGA
Biomarker

Definition

Indicates

PLGA
value

Significance

Clinical use

Ki-67

Cell
cycleassociated
antigen
Protooncogene

Cell
proliferation

<6.4%

Index
PLGA<ACC<M
EC

Increase in
transmembrane
receptor
tyrosine kinase
Staining
p63:
basal layer
p40:
myoepithelial
differentiation
Controls cell
proliferation

Absent

Overexpressed in
ACC

PLGA
stains +
for p63
and – for
p40

p63+/p40phenotype 100%
sensitive and 93%
specific for
PLGA

“only
suggestive
statistical
significance”
Differences
may or may
not be
significant
Diagnostic
promise in
PLGA

Variable

p53
overexpression
seen in 38% of
PLGA
PLGA stains
positive and
diffusely vs ACC
(may be variable)

Limited

PLGA: 60% coexpression
ACC: 13% coexpression
Expressed more
strongly in ACC
vs PLGA

Limited

PLGA and ACC
have increased
OPN expression
vs NSGT

Limited

Vimentin positive
in PLGA, and
weak in ACC

Vimentin
staining may
reliably
differentiate

C-kit
(CD117)

p63+/p40-

IHC
markers
for tumour
proteins

p53

Tumour
suppressor
protein

S-100

Low
molecular
weight
protein

Present in neural
crest cells,
chondrocytes,
adipocytes,
myoepithelial cells,
macrophages,
Langerhans cells,
dendritic cells,
keratinocytes

Majority
positive

Mammaglobin &
S-100

Mammaglobin
: glycoprotein

Present in
variable cells

Majority
positive
for both

CD43

Transmembrane
surface protein

Present in T
lymphocytes,
natural killer
cells, myeloid
cells
OPN involved
in malignant
tumour
invasion

Variable

Osteopontin,
CD44,
integrin
avb3

OPN:
phosphoglyco
protein

CD44 and
integrin
avb3:
ligands for
OPN

Cytokeratin
Vimentin

Cytokerati
n: Keratin
containing
intermediate

CK: Expressed
in epithelial
tissues

OPN
expression
increased;
CD44
reduced;
integrin
avb3
scattered
Positive
staining;
CK8 and
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Limited

Limited

filament
proteins

Vimentin:
intermediate
filament
protein

V: expressed in
mesenchymal
cells

CK18
increased.
Positive
staining

CEA

Glycolprotein

Functions in cell
adhesion;
biomarker for
colon cancer and
ovarian cancer

Variable

SMA,
MSA,
galactin-3,
cyclin D1,
GFAP,
EMA

Ubiquitous
proteins

Found in
muscle and
non-muscle
cell tissues

SMA:
decreased
MSA:
decreased
GFAP:
variable
EMA:
increased

Maspin &
MCM2

Maspin:

Maspin:

Variable

mammary
serin protease
inhibitor

prevents apoptosis
and decreases cell
invasion

MCM2:

MCM2:

Mini
chromosome
maintenance
proteins

Marker for cell
proliferation due to
role in DNA
replication
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between
PLGA and
ACC
CEA stains
positive in ACC,
but is decreased
and/or variable in
PLGA
ACC: increased
expression of
SMA, galectin-3
and cyclin D1
versus PLGA

Limited

PLGA and ACC
variably stain for
maspin and
MCM2; ACC
increased cell
proliferation
profile vs PLGA

Limited

Limited

1.1.1.9 Genetic studies in PLGA
1.1.1.9.1 Translocation, t(11;19)
Genetic translocation t(11;19) has been identified in MEC and was not found to be present
in PLGAs[30].
1.1.1.9.2 Gene fusions
1.1.1.9.2.1 MYB-NFIB
The MYB-NFIB gene fusion has been identified in ACC, and therefore, Persson et al.
chose to investigate this fusion in PLGA[34]. Their 2011 study revealed the MYB-NFIB fusion
was only present in 1 of 9 PLGA cases; they felt this highlighted the diagnostic difficulties in
separating PLGA from ACC[34]. Ultimately, they concluded the PLGA genome was genetically
stable[34].
1.1.1.9.2.2 ARID1A-PRKD1 and DDX3X-PRKD1
ARID1A and DDX3X encode proteins that are involved in DNA repair, and loss of their
function would result in aberrant DNA repair[26]. Furthermore, ARID1A has already been
identified to have a role in gynecologic malignancies[26]. The PRKD1 gene encodes a kinase
protein, which has been implicated in a variety of malignant processes, including: colorectal,
breast, esophageal, laryngeal, and others[26, 27, 37]. Moreover, PRDK1 kinases partake in signal
transduction, trafficking, migration, differentiation and proliferation of cells, as well as cell
adhesion[28, 37]. In 2014, Weinreb et al. searched for novel gene fusions in 2 cases of PLGA and
2 cases of CAMSG using next generation RNA sequencing[26]. Fusion ARID1A-PRKD1 was
found in one CAMSG case, and a DDX3X-PRKD1 fusion was located in the other CAMSG
case[26]. No fusions were found in the classic PLGA cases[26]. Weinreb et al. were able to
conclude that recurrent genetic rearrangements of PRKD1-3 and specific gene fusions ARID1APRKD1 and DDX3X-PRKD1 are associated with PLGA, in particular the CAMSG variant[26].
1.1.1.9.3 PRDK1 hotspot mutation
In their 2014 multi-centre study, Weinreb et al. identified the PRDK1 hotspot mutation
encoding p.Glu710Asp in PLGA[27]. By sequencing the genome of 3 PLGA cases, two
heterozygous single nucleotide variants were found in the PRDK1 gene, resulting in the same
amino acid substitution and consequential increased PRKD1 activity[27]. Subsequently, each
PLGA in their tumour bank were examined for this mutation, and it was present in 72.9% of
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cases[27]. The hotspot mutation was significantly associated with metastasis-free survival and the
group concluded it may offer a neoplastic advantage to PLGA tumour cells[27].
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1.2 Kallikreins (KLKs)
Human kallikreins are secreted serine proteases, which demonstrate a range of physiologic
and pathologic functions[49]. They are one of 178 human serine proteases, specifically belonging
to the S1A subfamily[50]. Human kallikreins are divided into two categories: plasma kallikrein
(KLKB1) and tissue kallikreins (KLK1-15)[51].
1.2.1 Plasma Kallikrein
KLKB1 is encoded by a single gene on chromosome 4q35, which consists of 15 exons and
does not share similarities with the tissue kallikrein family[51, 52]. Mature plasma kallikrein
functions as a major component of the plasma kallikrein-kinin system (KKS), releasing lysylbradykinin from high-molecular weight kininogen[53]. The KLKB1 gene consists of 15 exons and
does not share similarities with the tissue kallikrein family[51, 52].
1.2.2 Tissue Kallikreins
1.2.2.1 General Overview
Human tissue kallikreins are a single family of 15 highly conserved trypsin and
chymotrypsin-like serine proteases[54-56]. KLK1-15 are mapped to chromosomal locus 19q13.4
(Figure 2.1.2.1), which is the richest gene-containing chromosome, containing 261558 base
pairs[50, 53, 57, 58]. Furthermore, KLKs are encoded by the largest contiguous cluster of proteaseencoding genes in the human genome, and uniquely, they are not interrupted by any other nonKLK genes[49, 50, 57, 59, 60]. KLK genes are arranged closely, with as little as 1.5kb-32.5kb
between genes, and specific KLK gene lengths range from 4-10kb[50, 53]. The KLK tandem
cluster of genes is flanked by the testicular acid phosphatase gene (ACPT) on the centromeric end
and by the cancer associated gene (CAG), as well as Siglec-9 on the telomeric end[50].
KLK genes share many similar structural features including: exon and intron organization,
conservation of intronic intervals, and exon lengths[60]. KLK gene transcripts code for a single
chain serine protease pre-proenzyme of a fixed length, between 248 and 293 amino acids[50, 57].
The KLK genes and translated proteins share a high degree of homology; KLK proteins have an
amino acid sequence homology of ~40-80%, with KLK2 and KLK3 having the highest degree of
similarities[50]. A common characteristic of KLK proteins is their signal peptide motif (16-57AA),
which conveys that all KLK proenzyme forms are to be secreted[50]. All KLKs have 10-12
cysteine residues, which are thought to form disulfide bones, important to maintain the correct
conformation of the protein[50].
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Figure 1.2.2.1 The human tissue kallikrein gene cluster. This figure was originally published
in Journal of Biological Chemistry. Sotiropoulou G, Pampalakis G, Diamandis EP. Functional
roles of human kallikrein-related peptidases. 2009; 284(48): 32989-94. The figure is being
reproduced for educational purposes only and not for any commercial use. Figure is included in
the M. Sc. dissertation with attribution.
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Ultimately, KLKs are secreted serine proteases with a diverse expression and many
physiologic, as well as pathologic roles[49]. Moreover, KLKs are versatile signalling
molecules[60]. While they demonstrate expression in a wide variety of tissues, KLKs are primarily
expressed by secretory epithelial cells within glandular epithelia of many organs[49, 53, 56, 59].
1.2.2.2 Historical Development
The first kallikrein, KLK1, was identified in the 1930s by Kraut, Frey, and Werle[49]. The
group termed the proteolytic enzyme “kallikreas”, the Greek word for pancreas, due to its high
pancreatic expression[49, 61]. It wasn’t until 40 years later that “prostate specific antigen”, PSA,
was discovered as an identification agent in semen by forensics scientists[49]. It was later renamed
KLK3[62]. Initially, it was believed that KLK1-3 were the only members of the KLK family; but
in the late 1990s, 12 novel KLK genes were discovered through examination of the whole genetic
locus[49, 53]. Several groups reported other genes mapping to 19q13.4, and ultimately, all 15
KLK members were cloned[53]. KLK15 was the last member to be cloned, and this was completed
in 2001[49, 53]. A detailed map of the KLK gene locus was created by Borgono and Diamandis
in 2004[57, 63, 64].
Anecdotally, kallikreins were divided up into classical and non-classical groups[57].
KLK1-3 were denoted as classical, as these were the first members of the KLK family
discovered[53]. The non-classical group contains KLK4-15, as they were identified at a later
date[57, 63].
With significant advancements in the development of the kallikrein genetic family, a
comprehensive nomenclature system was proposed in a 2006 review by Lundwall et al[61]. KLK1
was the only KLK gene to retain the “kallikrein” name, denoted as kallikrein 1[63]. However, as
the remaining proteins in the KLK family do not display kininogenase activity, KLK2-15 were
termed “kallikrein-related peptidases”, followed by their genetic number symbol[61, 63]. For
example, KLK2 was re-named kallikrein-related peptidase 2[61]. This classification system also
differentiates between gene and protein denotation; genes are written in italicized text (e.g. KLK1),
whereas proteins are written in standard text (e.g. KLK1)[61].
1.2.2.3 Kallikreins as proteases at the genomic, mRNA, and protein level
Kallikreins are serine proteases, specifically belonging to the S1A subfamily of serine
proteases[50]. They may display trypsin or chymotrypsin-like activity, or both[54, 65]. KLKs
share characteristic features, some of which overlap with all serine proteases, and those that are
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unique to the KLK family. KLKs demonstrate invariant residues, they have an active site catalytic
triad (His57, Asp102, Ser195), and a conserved Gly, which stabilizes the peptide bond during
hydrolysis[57]. Unique features of the KLK family were well documented by Yousef and
Diamandis in their 2002 comprehensive review of KLKs as cancer biomarkers. These include: i)
KLK genes are formed by 5 codons, with the first codon always containing a 5’ untranslated
region, followed by a methionine start codon about 50bp away from the previous exon, and lastly,
a stop codon about 156bp away from the beginning of the last coding exon; ii) the catalytic triad
(His57, Asp102, Ser195) is conserved, histidine is always placed at the end of the second coding exon,
the aspartate is in the middle of the third coding exon, and the serine at the beginning of the fifth
coding exon; iii) the substrate binding pocket amino acid is either aspartate, representing trypsinlike specificity (KLK1,2,4,5,6,8,10, 11,12,13,14,15), or it is another amino acid, representing
chymotrypsin activity (KLK3,7,9) or other activity; iv) KLK proteins contain 10-12 cysteine
residues, with conserved positioning, forming 5-6 disulfide bonds; v) KLKs are under steroid
hormone control[51, 53, 66].
Many KLK genes exhibit copy number variations, which result from the use of alternative
and multiple promotors, based on their 5’untranslated regions[60, 67]. Furthermore, the 15
transcripts from the KLK genes may be alternatively spliced, producing many different mRNA
variants, thought to encode truncated proteins[49-51, 53]. The most common alternative splicing
events are skipped exons and exon extension, with exon truncation and intron retention
succeeding[49]. KLK3 is known to have at least 10 distinct mRNA variations, resulting from
alternative splicing[49]. Following an alternative splicing event, the mRNA variant may be
translated into functionally distinct proteins[49]. For example, KLK7 demonstrates mRNA
variants with different patterns of tissue localization[67]. Furthermore, these variants may have
roles in pathologic disease, and malignancies, as the consequential protein may have additional
functional roles, may lack classic KLK properties, or may be rendered non-functional[49]. It has
been stated that the product of alternative splicing most often encodes inactive KLK isoforms[60].
The involvement of serine proteases in cascade pathways has been well established;
substrates of serine proteases are often other serine proteases, which are activated from their
inactive form, into an active protein[53]. An example is the coagulation cascade. Similarly,
kallikreins are thought to participate in a variety of complex proteolytic cascade pathways,
involved in the regulation of physiologic and pathologic processes[54]. These include: semen
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liquefaction, skin desquamation, neurodegeneration and tumour promoting or inhibiting
effects[49]. The hypothesis that KLKs participate in proteolytic cascades is supported by the coexpression of numerous kallikreins in the same tissue, and the evidence that some kallikreins
activate each other[53]. For example, KLK3 can be activated by KLK15 and KLK4 has been
shown to activate KLK3[53]. Furthermore, KLKs may participate in proteolytic cascades that
involve nonkallikrein serine proteases; KLK3 can inactivate the N terminal fragment of the
parathyroid hormone related protein[53].
1.2.2.4 Activation of tissue kallikreins
The activation of KLK enzymes occurs through a complex proteolytic cleaving process, a
cascade referred to as the “KLK Activome” (Figure 2.1.2.2)[60]. Coordinated activation occurs
through this complex network and results in the activation of KLK enzymes that go on to regulate
normal and pathological processes[60]. As noted above, KLK genes are transcribed into a pre-proenzyme, which is a zymogen, as it is inactive in this form; this is single chained and of fixed AA
length[57]. This pre-pro-enzyme goes on to be proteolytically processed to an enzymatically
inactive pro-KLK, and these are secreted into the extracellular space by cleaving an aminoterminal signal peptide[57]. Ultimately, the pro-KLK is activated to a mature peptidase
extracellularly by cleaving the amino-terminal propeptide[51, 60]. KLKs may be auto-activated,
activated by another KLK, or activated by a different protease altogether[57, 63]. Proteases
implicated in the activation of KLKs include matrix metallopeptidases and the proteases of the
thrombostasis axis[59].
1.2.2.5 Regulation of kallikreins
The regulation of kallikreins occurs at various levels of their processing and activation into
functional proteases. This includes transcriptional, post-transcriptional and/or post-translational
levels, and therefore, resultant aberrations in their expression are seen with dysregulation at any of
these steps[60]. Kallikreins show differential expression, which may be tissue dependent, and
while some regulatory factors are unknown, others have been well studied[53, 66].
At the transcription level, steroid hormones are considered to be the primary regulatory
mechanism of KLK gene expression[51, 64, 68]. Moreover, epigenetic mechanisms, specifically
DNA methylation is also thought to have an important role in KLK transcription[60].
It has been well established that in endocrine tissues (e.g. breast, prostate, ovarian tissues),
all KLK expression is regulated by specific hormones including: androgens, estrogens, progestins,
20

Figure 1.2.2.2 KLK Activome and regulatory KLK cascades in normal physiology and
disease. This figure was originally published in Biochimica et Biophysica Acta (BBA) – Reviews
on Cancer. Pampalakis G, Sotiropoulou G. Tissue kallikrein proteolytic cascade pathways in
normal physiology and cancer. 2007; 1776 (1):22-31. The figure is being reproduced for
educational purposes only and not for any commercial use. Figure is included in the M. Sc.
Dissertation with attribution.
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glucocorticoids, and mineralcorticoids[56, 66, 69]. This is mediated directly by nuclear receptors,
which bind ligands, translocate to the nucleus and bind to cis-acting DNA sequences, known as
hormone response elements (HRE)[69]. These are found in the promoter/enhancer regions of many
KLK genes, including KLK2 and KLK3, and transcription is stimulated[66]. Indirect modulation
of transcription does not involve HRE, rather it involves a hormone-receptor complex interacting
with various transcriptional factors, resulting in trans-transcription[69].
Of note, the centromeric and telomeric KLK groups, KLK1-4 and KLK13-15 respectively,
are primarily upregulated by androgens, and the central KLK group (KLK5-12) is primarily
upregulated by estrogens[53]. Interestingly, the same KLK gene may be upregulated by two
separate hormones, in site-specific tissue; in prostate and breast cancer cell lines, KLK4 is
upregulated by androgens, whereas in endometrial cell lines, it is upregulated by estrogens[53, 69].
An exception is found in KLK1, which does not demonstrate hormone control in various tissues,
specifically uterine, renal, and salivary gland tissues[50].
Vitamin D signalling has also been well established as a transcriptional regulatory
mechanism of KLK expression[60]. Vitamin D3 upregulates KLK6 in various cancer cell lines,
including: head and neck, prostate, colon[66]. In normal keratinocytes, vitamin D3 has
demonstrated regulatory control over KLK10, in addition to KLK6, and thus, they have both been
implicated in skin carcinogenesis[55, 66].
Retinoic acid also contributes to the regulation of KLK genes. This may be accomplished
through a retinoic response element alone, or in combination with a series of receptors[66].
Retinoic acid demonstrates differential regulation of kallikreins; KLK10 is upregulated in breast
cancer cells; however, KLK2 and KLK3 is downregulated in prostate cancer cells[66].
Epigenetic mechanisms demonstrate transcriptional regulation of KLK gene expression.
DNA methylation modifications may silence certain KLK genes in cancer processes[60]. For
example, hypermethylation is thought to silence KLK10 in both ovarian and prostate cancer[69,
70]. Furthermore, DNA methylation of the KLK genome has been shown in the aberrant KLK
expression in acute lymphoblastic leukemia (ALL), prostate and breast cancer cells[51]. In ALL
and breast cancer, hypermethylation of exon 3 significantly down regulates KLK10[69].
A body of evidence suggests there is post-transcriptional regulation of KLKs by
microRNAs (miRNAs), which are small non-coding RNAs that regulate gene expression[70].
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These miRNAs function by partially annealing to their target RNA sequence, and decreasing
protein translation via an RNA-induced silencing complex (RISC)[70]. It has been observed that
one miRNA may target several KLK regions, therefore, may control multiple KLK proteins
simultaneously, silencing translation[70].
Another element of KLK regulation is at the post-translational level. Protease activation is
an irreversible process and therefore, the regulation of proteolytic cascades is tightly controlled[58,
64]. Several mechanisms have been implicated in the prevention of unwanted enzymatic
degradation of proteins, which include: zymogen activation, internal cleavage, and endogenous
inhibitors[64, 69]. Zymogen activation has been described previously, and occurs through a
diverse proteolytic cleavage cascade[69]. It should be noted that all pro-KLKs, with the exception
of KLK4, require the activity of trypsin-like serine protease for activation, and these include:
trypsin, enterokinase, trypsin-like KLKs, and auto-activation[69]. Internal cleavage has been noted
as a mechanism of inactivation in 6 of the 15 mature KLKs; cleavage occurs at the activate protease
either by autolysis or alternative proteases, resulting in degradation of the KLK protein[69].
Endogenous inhibitors known to regulate serine proteases, such as KLKs, include: serpins and
alpha-2 macroglobulin, both plasma inhibitors[69]. Serpins interact with KLKs in complex
pathways to deform and inactivate serine protease, whereas alpha-2 macroglobulin prevents other
proteases from binding the KLK by steric hindrance[69]. Microenvironments contribute to KLK
activity regulation, including the presence of certain ions and the pH of the tissues[58]. High
concentration of Zn ions in prostate tissue inhibits enzymatic activity of many KLKs, whereas
lower Zn ion concentrations are found in prostate cancer, contributing to higher KLK activity[51].
1.2.2.6 Physiologic function of kallikreins
KLKs are expressed in a wide variety of tissues in the body, including, but not limited to
pancreas, heart, lung, CNS, salivary glands, thyroid, breast, testis, ovaries and prostate[53, 56, 57,
71]. An exhaustive list of tissues expressing KLKs is presented in Figure 2.1.2.3, adapted from
Yousef and Diamandis’ 2001 review of KLKs[71]. Notably, it also demonstrates that KLKs may
be co-expressed in normal tissues, but that this expression occurs at different levels[60, 71]. The
physiologic roles of KLKs have been best established for KLK1-3[53]. Physiologic processes that
KLKs are involved in include: tissue kallikrein-kinin system, skin desquamation, innate immunity,
semen liquefaction, enamelogenesis, and degradation/remodeling of the extracellular matrix
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(ECM)[53, 55]. Additionally, KLKs help regulate blood pressure, and are involved in electrolyte
balance in ECM remodeling, prohormone processing, and neural plasticity[49].
KLK1
The highest expression of KLK1 is found in the pancreas, kidney, and salivary glands; it has also
been found in sweat glands, pituitary gland, intestines, uterus, prostate, testis, breast, placenta, and
neutrophils[50, 71]. The primary function of KLK1 is its involvement in the tissue KKS as a
kininogenase enzyme, releasing lysyl-bradykinin from low-molecular weight kininogen[53]. It is
also known to cleave pro-insulin, pro-renin, LDL, the precursor for atrial natriuretic factor,
vasoactive intestinal peptide, procollagenase, and angiotensinogen[50].
KLK2
KLK2 shows highest expression in the prostate, and is also found in breast, salivary gland, and
thyroid tissue[71]. It plays a role in seminal plasma liquefaction; however, it is a smaller role than
that of KLK3[53, 57].
KLK3
The prostate is where KLK3 is most highly expressed, but it is also found in breast, thyroid,
tracheal, and lung tissues[71]. KLK3 has been found in several fluids apart from its high
concentration in semen, including breast cyst fluid, nipple fluid, milk of lactating women, and
amniotic fluid[53]. KLK3 has a primary role in seminal plasma liquefaction, and through
hydrolysis, liquefies the seminal plasma clot after ejaculation[53, 57].
KLK4
The highest expression of KLK4 is found in the prostate; it has also been found in breast, thyroid,
testis, uterine, adrenal, colon, and spinal cord tissues[71]. Furthermore, KLK4 is thought to have
a primary role in the biologic function of enamel maturation and tooth development[50].
Specifically, KLK4 degrades enamelin to allow for apatite growth[50].
KLK5
The highest expression of KLK5 is found in breast, brain, testicular, and skin tissues; it has also
been found in salivary glands, thymus, CNS, prostate, thyroid, esophageal and tracheal tissues[71,
72]. KLK5 takes part in the skin desquamation proteolytic cascade in the stratum corneum, along
with KLK7[57, 68]. It also has a role in seminal plasma liquefaction[57].
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KLK6
The highest expression of KLK6 is found in CNS, breast, renal and uterine tissue; it has also been
found in salivary glands, the spleen, heart, thymus, prostate, liver, thyroid, placenta, trachea and
testis[71, 73]. KLK6 is secreted by oligodendrocytes and plays a primary role in remyelination
and in maintaining a normal myelinated state[74].
KLK7
The highest expression of KLK7 is found in skin, CNS, renal and breast tissues; it has also been
found in salivary glands, thymus, uterus, thyroid, placenta, trachea, testis and ovaries[71]. Others
have reported high expression in normal cervix, ovaries, testes, esophagus, stomach and low
expression in normal colon[68]. KLK7 has shown strong staining patterns for NSGT[67]. KLK7
has a significant role in skin desquamation, and demonstrates co-expression with other KLKs in
this proteolytic function[57, 68]. KLK5 and KLK7 function to degrade corneodesmosomes, which
interconnect the stratum corneum; this degradation is a pre-requisite for skin desquamation[68].
Furthermore, KLK7 is co-expressed with KLK14 for additional skin desquamation activity[55].
KLK8
The highest expression of KLK8 is found in CNS, skin and ovarian tissues; it has also been found
in esophagus, testis, tonsillar, renal, breast, and salivary gland tissue[54, 71]. KLK8 has been
demonstrated in a number of bodily fluids: breast milk, amniotic fluid, seminal fluid, and
serum[54].
KLK9
The highest expression of KLK9 is found in the thymus, testis, CNS and trachea; is has also been
found in breast, prostate, salivary glands, ovaries and skin[71].
KLK10
The highest expression of KLK10 is found in breast, ovarian, testicular, and prostate tissues; it has
also been found in the small intestine, lung, colon, pancreas, uterus, CNS, salivary glands and
trachea[71]. KLK10 has demonstrated high expression in the islets of Langerhans in the pancreas,
and may have a role in regulation of insulin, glucagons, somatostatin, and pancreatic
polypeptide[55]. KLK10 also participates in the proteolytic process of skin desquamation, which
may be mediated through the processing of desmoglein1 (DSG1)[55].
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KLK11
The highest expression of KLK11 is found in brain, skin, salivary gland, stomach, uterus, lung,
thymus, prostate, spleen, liver, small intestine, and trachea; it has also been found in the heart, fetal
liver, breast, thyroid, and skeletal muscle[71].
KLK12
The highest expression of KLK12 is found in salivary glands, stomach, uterus, trachea, prostate,
thymus, lung, colon, brain, breast, and thyroid; it has also been found in testis, pancreas, small
intestine, and spinal cord[71].
KLK13
The highest expression of KLK13 is found in breast, prostate, salivary glands, and testis; it has
also been found in the lung, heart, adrenal, colon, thyroid, and tracheal tissues[71]. Along with
KLK10, KLK13 has demonstrated high expression in the islets of Langerhans in the pancreas, and
may have a role in regulation of insulin, glucagons, somatostatin, and pancreatic polypeptide[55].
KLK14
The highest expression of KLK14 is found in the CNS; it has also been found in breast, thyroid,
uterus, thymus, colon, spleen, placenta, small intestine, kidney and bone marrow tissues[71].
Others have reported high expression in normal brain tissue, along with prostate, testis, and
thymus, with low expression in normal colon tissues[68]. Moderate immunohistochemical staining
with KLK14 has been seen in salivary gland tissue[75]. KLK14 is involved in skin desquamation,
and as noted previously, demonstrates co-expression with KLK7 in this proteolytic activity[57].
Moreover, KLK14 is thought to contribute to the hemostasis of seminal plasma[68].
KLK15
The highest expression of KLK15 is found in the thyroid, salivary glands, and prostate; it has also
been found in adrenal, colon, testicular, and renal tissues[71].
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Figure 1.2.2.3 KLK expression in human tissues. This figure was originally published in
Endocrinology Reviews. Yousef GM, Diamandis EP. The new human tissue kallikrein gene family:
structure, function, and association to disease. 2001;22(2): 184-204. The figure is being
reproduced for educational purposes only and not for any commercial use. Figure is included in
the M. Sc. Dissertation with attribution.

27

1.2.2.7 Kallikreins in pathologic states
Dysregulation of KLK expression leads to various pathologic states and aberrant regulation
of KLKs has been implicated in a variety of diseases. This includes hypertension, renal disease,
skin disorders, inflammation, neurodegenerative disease, and cancer[57, 60]. As demonstrated
previously, KLKs show co-expression in physiologic states, as such, when KLKs are dysregulated,
the co-expressed KLKs are coordinated[55].
Specific kallikreins have been implicated in certain diseased states. The aberrant regulation
of KLK1 is associated with skin abnormalities[50]. KLK7 dysregulation has been implicated in
chronic itchy dermatitis, psoriasis, and atopic dermatitis[50]. KLK8 has notable upregulation in
conditions with hyperkeratotic features, such as seborrheic keratosis, psoriasis vulgaris, lichen
planus, and squamous cell carcinoma, as compared to normal skin tissue, where minimal KLK8 is
localized[50]. Aberrant expression of KLK14 results in pathologic skin conditions like atopic
dermatitis, acute eczematous atopic skin[68].
KLK6 has been suggested as a potential biomarker for Alzheimer’s disease, as decrease
levels of KLK6 in CSF have been observed in Alzheimer’s patients, and therefore, it has been
suggested as a risk factor for this disease[50, 60]. KLK8 has been noted to be upregulated in the
hippocampus of patients with Alzheimer’s disease[50]. KLK10 upregulation, along with KLK7
co-expression and upregulation, has been linked with Alzheimer’s disease[50, 55]. Additionally,
KLK6 dysregulation has been implicated in Parkinson’s disease[50]. KLK6, KLK7, and KLK10
expression has been demonstrably lower in patients with frontotemporal dementia[50].
Many KLKs demonstrate aberrant expression in malignant pathologic processes, and as
such, this will be discussed in a separate section.
1.2.2.8 Kallikreins and malignancy
KLKs have been shown to be aberrantly regulated in almost all human solid tumours, and
in particular, dysregulation of KLKs in steroid-dependent cancers (e.g. breast, prostate, ovarian)
has been well documented[58, 76].
KLKs 1,3,5-10, and 12-15 have demonstrated aberrant expression in breast cancer cells[50,
58, 64]. KLK6 becomes downregulated in metastatic breast cancer cells, when compared to
primary breast cancer cells and normal breast tissue[73]. KLK7 is downregulated in breast cancer
tissue; however, contradictory reports are found in the literature[67, 68, 77]. KLK10 and 12 are
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associated with breast cancer, and demonstrate downregulation[53, 55]. KLK13 is downregulated
in a subset of breast carcinoma[53]. KLK14 is over expressed in breast cancer cells[68].
KLKs 2-11, and 13-15 have been found aberrantly expressed in ovarian cancer cells[58,
64]. For example, KLK4 is expressed in ovarian cancer, but it not seen in normal ovarian
tissue[50]. KLK5 demonstrates higher expression in late stage serous ovarian carcinoma[73].
KLK6, 7, 8, 13 and 14 demonstrate over-expression in ovarian cancer[53, 67, 68, 76, 77].
KLKs 2-6, 10,11, and 13-15 have demonstrated dysregulation in prostate cancer[58, 64].
In prostate cancer, serum levels of KLK3 may be dramatically increased; KLK3 expression is
primarily confined to the glandular ducts and when glandular architecture is lost in malignancy, it
is postulated KLK3 is released into the blood stream[56]. In the prostate tumour cells, KLK3
expression is downregulated[64]. KLK7 is downregulated in prostate cancer cells[68, 77]. KLK14
is expressed in prostate cancer to a similar degree that KLK2 and 3 are over-expressed[68, 75].
In lung adenocarcinoma, KLK5, 7 and 8 antibody staining was positive in the nucleus of
the tumour cells[67, 75]. KLK5 is relatively downregulated in testicular cancer, when compared
to high levels of KLK5 expression in normal testis[53, 72]. KLK7 is upregulated in cervical, colon,
intracranial, oral squamous cell and pancreatic cancer cells, and down regulated in melanoma and
kidney cancer cells[67, 68, 77]. KLK10 is upregulated in colon cancer cells, with advanced
colorectal tumours demonstrated high KLK10 expression[55, 63]. Dysregulation of KLK10 has
been linked with testicular cancer, and along with co-expression of KLK6, skin carcinomas[55].
KLK14 has also been demonstrably upregulated in salivary gland malignancies[68].
Aberrant KLK expression has been implicated in various malignant pathological processes,
and various stages of cancer development[68]. KLKs have been postulated to maintain a dual role
as both stimulatory and inhibitory factors that modulate tumour behaviour[67]. Furthermore, KLK
dysregulation can promote carcinogenesis or inhibit cancer activities, and this may be tumour-site
specific[55]. Experimental evidence has demonstrated that KLKs may influence malignant growth
potential, angiogenesis, tumour invasion and metastasis via proteolytic cascades[55, 75].
Specifically, the proteolytic processing of growth factor-binding proteins, activation of growth
factors and other proteases, releasing angiogenic or anti-angiogenic factors, and the degradation
of ECM components may promote tumorgenesis[55, 75].
Specific KLKs have been implicated in tumour progression. KLKs 1-4,6,7, 13 and 15
function in ECM degradation, and angiogenesis, ultimately contributing to tumour invasion and
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metastasis[64, 76]. More specifically, KLK7 is known to degrade ECM components in pancreatic
cancer cells, thereby promoting metastasis; fibronectin is degraded, which leads to tumorgenesis
and desmosomal proteins are degraded, decreasing cell adhesion and promoting tumour
invasion[67, 68]. KLK7 role in tumour invasion and progression has been suggested, as in prostate
cancer cells, the protease induces epithelial to mesenchymal transition[68]. KLKs 1-3 are involved
in tumour growth regulation via their actions on insulin growth factors[64]. KLK14, which is
produced by colon tumour cells, has been shown to activate proteinase-activating receptors
(PARs), contributing to tumorgenesis[68]. Interestingly, KLK3, 6, and 13 also show antiangiogenic properties[64].
1.2.2.9 Kallikreins and salivary gland neoplasia
The association between kallikreins and salivary gland tissue has been well established.
Multiple KLKs have been found in NSGT, including KLK1,2,9,10,13; moreover, most KLKs have
been detected in salivary gland tissues by RT-PCR and other methodology[73, 76]. Some KLKs
have demonstrated high expression in NSGT, which may indicate an active KLK proteolytic
cascade in these tissues[67].
A summary of the findings to date on KLKs in salivary gland benign and malignant
neoplasia will now be presented. KLK3 has been found via in-situ hybridization in NSGT;
however, this finding was not corroborated by Darling et al., who concluded KLK3 was not
expressed in salivary gland tumours[72]. KLK5 is not expressed in NSGT; scant positive IHC
staining has been seen for PA, ACC, ANOS, MEC, but none was deemed significant[72]. KLK6
is expressed in salivary gland tumours; however, it is downregulated as compared with NSGT and
the IHC staining demonstrated in tumour cells is non-specific[73, 76]. KLK7 has been detected in
NSGT, and has been associated with salivary gland neoplasms, including: PA, ACC, MEC[67].
Significantly higher staining with KLK7 antibody has been seen in PA and ACC, as compared
with MEC, which demonstrated both ductal and non-ductal staining, but was akin to NSGT stain
levels[67]. This finding suggests KLK7 may have a role in myoepithelial differentiation[67].
Moreover, the expression of KLK7 in both NSGT and tumour tissue is similar to KLK14, which
suggests possible cascade effect leading to tumorgenesis[67]. Nuclear staining in salivary gland
tumours has also been seen with KLK7 antibodies[67]. Interestingly, the level of KLK7 expression
has not shown any association with tumour stage, grade, site of tumour, or patient
demographics[67]. KLK8 has been detected in NSGT, and high levels of expression are seen in
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most salivary gland tumours[54]. Darling et al. found KLK8 antibody staining was significantly
higher in ductal cells of NSGT and significantly higher in salivary gland malignancies[54]. KLK10
demonstrates strong expression in NSGT, and staining of malignancies with KLK10 antibody is
not significantly different; however, PA demonstrates significantly lower expression than
NSGT[55]. At the cellular stain level, KLK10 shows higher intensity staining in serous acinar
cells, and equivalent mucous acinar and ductal cell staining, when compared to NSGT[55]. KLK13
has been linked to NSGT; PA shows lower KLK13 staining comparatively, whereas PLGA, ACC,
ANOS stains significantly higher for KLK13 than NSGT[76]. Furthermore, KLK13 staining has
been documented as higher in MEC and ACI (acinic cell), yet it is not significant[76]. KLK14
expression has been noted in NSGT, with over-expression noted in PA (statistically significant)
and ACC, and decreased expression in MEC[75]. Furthermore, nuclear specific staining has been
associated with KLK14 in salivary gland tumours[75]. Of interest, Darling et al. showed a
correlation between KLK7, 10, and 14 expression in ACC[55].
To the authors knowledge, KLK expression has only been studied in PLGA by Darling et
al., who examined the expression of KLK13 in 13 samples of PLGA[76]. They found KLK13
stained greater in malignant salivary gland tumours, than benign salivary gland tumours and
normal salivary gland tissue[76].
1.2.2.10 Kallikreins as biomarkers
Biomarkers have been widely adopted in medicine for the detection and measuring of
biologic or disease states[78]. Biomarkers objectively measure substances, structures or processes
in the body that influence or predict the incidence of outcome or disease[78]. Biomarkers have the
potential to be used clinically in the diagnosis, prognosis, and recurrence of disease, with the goal
of reducing mortality[78]. Ideally, a tumour biomarker would have the following characteristics:
(1) expression in the pre-malignant or early malignant stage of the disease, (2) expressed in all
patients with the specific malignancy at detectable levels, (3) accessible and non-invasive, (4) the
quantity of expression equating to tumour bulk, clinical behaviour, or disease progression, (5)
demonstrates a relatively short-half live to yield changes when disease in remission and/or to
monitor disease progression, (6) measurable with a standardized, reproducible, and valid objective
and quantitative assay[79]. Ultimately, biomarkers which are used for diagnostic and prognostic
purposes, as well as for drug targeted therapies, would ideally be both highly specific and
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sensitive[80]. Biomarkers may be categorized into pharmacodynamic, prognostic, or
predictive[80].
Kallikreins have emerged as powerful tumour markers[57]. The most well-known
biomarker is KLK3, also known as prostate specific antigen (PSA), and it has been regarded as the
most valuable biomarker in clinical practice for prostate cancer diagnosis and monitoring of high
risk populations [49, 57, 60, 76]. A serum PSA test indicates a measurement of the “total” immunereactive concentration of PSA in serum or plasma[56]. Implemented since the late 1980s, the PSA
test, along with improved prostate cancer treatments, has contributed to a decrease age-adjusted
death rate from prostate cancer of 40% in the United States[56]. The PSA test was validated by
two high-quality European randomized controlled trials in the 1990s, demonstrating significant
reduction in mortality in prostate cancer by screening men 55-69 years every two to four years and
men 50-64 every two years[56]. Controversy over the widespread use of PSA screening arose with
the U.S. trial, “Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO)”, as it
concluded there was no statistically significant different in prostate-specific mortality risk between
those screened and those who were not[56].
Much controversy continues to exist on routine PSA screening, and pros and cons for PSA
testing have been put forth. The potential benefits from PSA testing may include detection of
disease prior to metastatic spread, earlier detection leading to more treatable disease and overall
mortality reduction from prostate cancer; other benefits include the potential to diagnose benign
prostatic hyperplasia (BPH)[56, 81]. Limitations of PSA screening include its lack of specificity,
as many biologic conditions can cause an increase in PSA levels, such as BPH, increased age,
prostatitis, and transient increase of PSA with ejaculation[81]. Obese men often demonstrate lower
PSA levels, and certain drugs may also affect PSA levels (e.g. 5-alpha-reductase inhibitors)[81].
The PSA assay is not diagnostic alone, and if malignancy is suspected, additional tests will be
required (e.g. tissue biopsy); moreover, a single PSA test will not provide information on the
aggressiveness of disease. Harmful outcomes from the use of PSA include detecting prostate
cancer which would not have become clinically significant in the patient’s lifetime, and therefore
put the patient through treatment they may not have required[81]. If the PSA is not elevated, this
may provide false reassurance to the patient, as disease could still be present[81]. There is also
potential for false-positives, leading to unnecessary biopsies with accompanying serious
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complications, over diagnosis, unneeded treatment with potential harmful sequelae (e.g
impotence), and considerable anxiety[56, 81].
This significant argument both for and against the routine use of PSA testing continues to
be controversial and in 2012, the United States Preventative Services Task Force recommended
against PSA screening; however, the American Urological Association (AUA) and the American
Cancer Society (ACS) continue to recommend PSA testing[82]. In an effort to increase the
specificity of PSA testing, logistic regression models that use the ratio of KLK2 to free PSA and
the ratio of free PSA to total PSA have been useful in differentiating between BPH and prostate
cancer[83].
Additional KLKs have been suggested as possible biomarkers in prostate cancer. KLK5
and KLK11 have been shown to be favourable prognostic markers in prostate cancer; KLK15 has
been noted as an unfavourable prognostic marker[50, 53].
KLKs have also been put forth as potential biomarkers for a variety of other malignancies.
In ovarian cancer, KLK4-7, 10, 11, and 15 have all shown to be markers of unfavourable
prognosis[50, 53, 72, 75]. KLK4 has been determined to be an independent indicator of poor
prognosis in grade 1 and 2 ovarian tumours[50]. KLK7 has contradictorily been noted as both a
favourable and unfavourable marker of prognosis; Dorn et al. reported that patients with high
expression of KLK7 had significantly two-fold lower risk of death, and that KLK7 was
significantly associated with overall and disease free survival[77]. KLK8,9,13, and 14 have been
linked as favourable prognostication factors in ovarian cancer[50, 53]. KLK8 and KLK13 are
upregulated in ovarian tumours and it’s higher expression has been found to be favourable[76].
Devetzi et al. concluded that KLK5, 11 and 14 are markers for ovarian cancer diagnosis, KLK6,8
and 10 are markers for ovarian cancer diagnosis, prognosis and monitoring of disease[68].
In breast cancer, KLK5,7,10 and 14 have all shown to be markers of unfavourable
prognosis[50, 53, 72]. KLK10 and 14, while noted as poor prognostic factors, have also been
demonstrably downregulated[50]. KLK10 was also found to be a predictor of invasiveness in
ductal breast carcinoma[53]. In contrast, while it is noted to be unfavourable above, KLK7 has
also been reported as a favourable prognostic marker in breast cancer[67]. Additional favourable
prognostic markers include: KLK15[50, 53].
In colon cancer, KLK7, 10, and 14 have been shown as markers of unfavourable
prognosis[55, 68]. Specifically, KLK7 has been implicated as an unfavourable marker for overall
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survival in colorectal cancer[68]. KLK10 and KLK14 are upregulated in colon cancer cells, and
high expression of these proteases is seen in advance colorectal tumours, with higher KLK10 and
KLK14 expression associated with decreased disease-free survival and overall survival rates[55,
63, 68]. Lastly, in pancreatic ductal adenocarcinoma, KLK6 and 10 are co-expression and noted
to confer a poor prognosis[55].
KLKs may also prove useful as potential targets for therapy and monitoring disease
progression. PSA is once again an example of this, as there has been significant work on PSA
targeted drug therapy, and sequential PSA testing is considered valuable post prostate cancer
treatment, as a rising level often indicates recurrence[81]. Furthermore, KLK4 has been shown to
be a protein marker for resistance to paclitaxel therapy in the treatment of ovarian cancer[50]. In
ovarian cancer, KLK7 may be useful in predicting surgical success outcomes, and may also have
value in assessing response to chemotherapy and/or the overall and disease-free survival[77].
To date, no KLK has been used as a biomarker in salivary gland malignancies. However,
as most KLKs have been detected in salivary glands, this lends them to being useful as biomarkers
of salivary gland malignancy, with potential to aid in diagnosis, prognosis and monitoring of
disease[73].
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1.3 Hypothesis, Rationale and Aims
1.3.1 Hypothesis
In this study, we hypothesize that human tissue kallikreins (KLK) are aberrantly expressed
in polymorphous low-grade adenocarcinoma (PLGA), as compared to normal salivary gland tissue
(NSGT). We further hypothesized that KLK expression, whether increased or decreased, may be
demonstrated specifically in tumour cells.
1.3.2 Rationale
The diagnosis of PLGA, the second most common malignant salivary gland tumour of the
minor glands, can often be challenging. This may be attributed to its various histologic
appearances, which overlap with other salivary gland neoplasia. It is well established that delayed
diagnosis of malignancies results in poorer patient outcomes, as well as increases patient
morbidity[1].
KLKs have been recognized as valuable tumour biomarkers, as they demonstrate aberrant
regulation in malignant processes[67]. The most well-known is KLK3, or prostate specific antigen,
which has contributed advancements to the diagnosis and monitoring of prostate adenocarcinoma,
while also generating a potential therapy target[49].
KLKs have been extensively studied in many glandular tumours, including breast and
prostate carcinoma. KLK expression has previously been shown in NSGT[73, 76]. Furthermore,
aberrant regulation of KLKs has been linked to other salivary gland tumours. This suggests their
potential use as biomarkers in salivary gland neoplasms[67]. KLK levels in PLGA may lend
themselves as diagnostic markers and prognostic markers to better recognize PLGA and
differentiate tumour clinical behaviour. Lastly, the detection of KLKs in serum or other bodily
fluids may provide a rapid and minimally invasive means of diagnosis in PLGA.
To date, examination of KLK expression in PLGA is limited to KLK13 only. To the authors
knowledge, this study is the first to look at the expression of KLK1-15 in PLGA, both at the level
of mRNA and protein.
1.3.3 Aims
1. To determine levels of KLK (KLKs1-15) mRNA in formalin fixed paraffin embedded
PLGA tissue samples, using real time polymerase chain reaction.
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2. To determine if KLK expression is tumour cell-specific, by analyzing
immunohistochemical expression of specific KLKs (KLK 7, KLK8, KLK10, KLK11, and
KLK14) in PLGA tissue samples. The staining scores of each PLGA sample will then be
compared to specific KLK mRNA levels.
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Chapter 2
2.0 Experimental Materials and Methods
2.1 Tissue Specimens
2.1.1 Tumour Criteria
Cases of polymorphous low-grade adenocarcinoma were retrieved from the archives
between 1987-2013 at University Hospital, London Health Sciences Centre and the Division of
Oral Pathology, Schulich School of Medicine & Dentistry, Western University. Original
hematoxylin and eosin (H&E) stained slides were reviewed to confirm a diagnosis of PLGA, and
to verify enough tumour tissue for experimental use. Blocks of formalin-fixed, paraffin-embedded
(FFPE) PLGA tissue were obtained for suitable cases. Some samples required re-embedding in
paraffin wax and repeat H&E stain to confirm enough tumour tissue for our studies. Cases that did
not have an original slide or FFPE blocks were omitted. A total of 19 PLGA tumours were
obtained.
2.1.2 Patient data collection from PLGA samples
Data was obtained from each PLGA case. This included patient demographics (age,
gender), tumour clinical features and microscopic findings. Specific clinical features recorded
were the tumour site and whether not the tumour was a recurrence. Histologic findings noted were
morphology (e.g. trabecular, cribriform), perineural invasion, encapsulation, and degree of
infiltration. Table 3.1.1 lists patient demographics, including sex, age, location of the tumour and
year of biopsy for each PLGA sample.
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Table 2.1.1: Patient Demographics for PLGA Samples
Sample Pt
#
Age

Sex

Location

Year
of
Bx
1994

1

56

F

2

51

F

3

78

F

L posterior
hard palate

2002

4

77

M

2001

5

67

M

6

50

F

7

59

M

8

76

M

9

63

F

10

49

F

11

17

F

12

65

F

13

83

M

14

76

M

R buccal
mucosa
Upper lip
Mucosa
L hard
palate
L soft
palate
L upper
lip
Hard and
soft palate
jxn
R buccal
mucosa
mid hard
palate/soft
palate jxn
L hard
palate
Sublingual
gland
Soft palate

15

38

F

2007

16

54

F

17

65

F

L buccal
vestibule
R
hard/soft
palate jxn
R buccal
mucosa
L buccal
mucosa
R soft
palate

18
19

F
61

F

Posterior
palate
Soft palate 2009

2008
2009
2005
2013
2003
2009
2007
2009
2002
2004

2010

1992
1989
1991

38

Table 2.1.2: Patient Demographics for NSGT Samples. This table was originally produced in
Expression of kallikrein-related peptidases (KLKs) in Adenoid Cystic Carcinoma. Kerr, Zachary
R. Electronic Thesis and Dissertation Reporitory. Paper 4096. The table is being reproduced for
educational purposes only and not for any commercial use. Figure is included in the M. Sc.
dissertation with attribution.
Sample
#
1

Pt
Age
75

Sex

Location

F

Left gingiva

2

38

F

Left lower lip
mucosa

3

53

F

Lower lip

4

20

M

5

24

M

6

68

F

Right lower
lip
Right buccal
mucosa
Left lower lip

7

24

F

8

20

F

Floor of
mouth
Lower lip

9

47

F

Lower lip

10

42

F

11

18

M

Right lower
lip
Left lower lip

12

68

M

Uvula

13

55

M

14

33

F

Right lower
lip
Lower lip

15

58

F

Left hard
palate
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2.1.3 Tissue sectioning
The regions representative of PLGA tissue on the H&E stained slides were circled and
matched to the same region on the FFPE tissue block. A scalpel was used to encircle the tumour
tissue by scoring the paraffin. A microtome (Microm HM 325, GMI Inc., Ramsey, MN, USA,
SKU# 8243 30 1006) was used to prepare 3x10µm tissue curls from each of the 19 PLGA PPFE
tissue blocks. The tissue samples were not selected for tumour sample only; therefore, specimens
consisted of tumour tissue and surrounding non-tumour tissues. The specimens were then placed
in 1.5mL collection tubes.
2.1.4 Normal Tissues
Previous work on characterizing KLK mRNA expression in NSGT has been completed in
the Division of Oral Pathology, Schulich School of Medicine & Dentistry, Western University.
Kerr et al. used 15 samples of NGST, all from minor salivary gland tissue. Demographic
information for the NSGT Specimens is listed in Table 3.1.2. The same experimental design to
determine KLK expression in PLGA was used for the NSGT samples, and this is outlined below
[84]. These results were used as comparison against PLGA tumour tissue results.
2.2 RNA isolation from formalin-fixed, paraffin-embedded tissue
2.2.1 Deparaffinization
For each sample of PLGA tumour, one 3x10µm curl of FFPE tissue was placed in a 1.5
mL reaction tube and 800µL of Xylene was added. The tube was vortexed and incubated for 5
minutes. Subsequent centrifugation was completed for 2 minutes at maximum speed (12000-14000
x g) and the supernatant was discarded via aspiration. Deparaffinization steps were repeated.
Following deparaffinization, 800µL of absolute ethanol was added and the pellet was dislodged.
Samples were centrifuged at maximum speed and the supernatant was discarded. Next, 800µL of
70% ethanol was added to the tube. Following another centrifugation, the samples were lysed using
tissue lysis buffer (Roche Applied Science, Mannheim, Germany, Catalogue number: 04 823 125
001).
2.2.2 RNA Isolation Protocol
High Pure FFPE RNA Micro Kit (Roche Applied Science) was used to isolate RNA from
each of the samples. Following tissue digestion, proteinase K was added to the tubes and the
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samples were incubated for 3 hours at 55°C. Next, 200µL of Binding Buffer and 200µL of ethanol
(absolute) was added. Proteinase K is a broad-spectrum serine protease, which is added to digest
protein and remove contamination from the preparation of nuclei acids; proteinase K rapidly
inactivates nucleases which may otherwise degrade DNA or RNA during purification. Ultimately,
this enzyme inactivates RNases and DNases improving the stability of these nucleic acids, and
removes contaminates yielding pure DNA and RNA[85]. Following this step, the lysate was added
into the upper reservoir of the RNA column tube. Genomic DNA was eliminated using DNase
solution. All other steps were performed as suggested by the manufacturer. RNA isolated was
stored at -80 °C until time of analysis.
2.2.3 RNA Quantification and cDNA synthesis
Isolated total RNA was quantified using Qubit Fluorometer (Invitrogen, Carlsbad, CA,
Catalogue no Q32866). The Qubit Fluorometer is able to accurately detect RNA concentrations of
10pg/uL to 1ug/L. A fluorescent dye binds specifically to RNA; initially these dyes have low
fluorescent properties, but emit a higher signal once bound to RNA, which is quantifiable. Based
on the lowest RNA yield, minimum of 0.32ng of total RNA was selected for cDNA synthesis. The
iScript cDNA synthesis kit (Bio-Rad Laboratories (Canada) Ltd. Mississauga, ON, Catalogue
number: 1708890) was used to synthesis complementary DNA (cDNA) from previously isolated
RNA.
2.3 SYBR Green Real Time Polymerase Chain Reaction (PCR)
The CFX Connect PCR Detection System (Bio-Rad Laboratories (Canada) Ltd,
Mississauga, ON) was used to measure transcript levels. Source of primers is indicated in Table
3.3.1. PCR reaction consisted of 10µL RT2 SYBR® Green qPCR Mastermix (Qiagen, Toronto,
ON Catalogue No 330500), 2µL primers, 2µL cDNA, and 6uL H2O. The RT-qPCR cycle protocol
was completed as follows: one cycle of 10 minutes at 95°C for activation of Taq DNA polymerase,
40 cycles of 15s at 95°C and 40 cycles of 1minute at 60°C for DNA amplification. Melting curve
analysis was included in all qPCR studies.
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Table 2.3.1: Qiagen Catalogue numbers for primer assays used in Custom PCR Plate
Primer Assay

Catalogue Number

KLK1

QT00020664

KLK 2

QT00088466

KLK3

QT00027713

KLK4

QT00495159

KLK5

QT00010437

KLK6

QT00013972

KLK7

QT00028343

KLK8

QT00017689

KLK9

QT00057190

KLK10

QT00039816

KLK11

QT00011011

KLK12

QT00067977

KLK13

QT00029876

KLK14

QT00039928

KLK15

QT00035735

β-actin

QT01680476
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2.4 Data analysis for PCR
Data was analyzed by ΔΔCT using CFX Manager. CT is defined as the threshold cycle, which
occurs when the fluorescence level reaches a certain amount in the PCR experiment[86].
ΔΔCT is a method of relative quantification, and calculates relative gene expression in a
target and reference samples in comparison to a data normalizing gene[86]. Data was
normalized to β-actin and normal salivary gland tissue mRNA was used as the comparator for
ΔΔCT.
2.5 Statistical Analysis
For each KLK, the mean of mRNA expression in tumour samples was calculated, as was
the standard error of mean. Data was tested for normality and non-parametric statistical analysis
was determined to be appropriate. Statistical testing was performed with Mann-Whitney U Test
and significance was set at p<0.05.
2.6 Assay Methods
2.6.1 Immunohistochemistry sample selection
Samples were selected for immunohistochemistry after analyzing KLK mRNA levels from
PCR data. Samples exhibiting relatively lower or higher mRNA levels of specific KLK were
included. Table 3.6.1 outlines the samples used for immunohistochemistry experiments.
2.6.2 Immunohistochemistry
For the immunohistochemistry experiments, a standard immunoperoxidase staining
method was employed. An indirect technique was used to localize tissue expression of KLK 7, 8,
10, 11, and 14 in PLGA tissue samples. Positive controls (Table 3.6.2.1) and negative controls (no
primary antibody) were included for all staining experiments.
2.6.3 Antibody Selection
For our study, the primary antibodies were donated by Dr. E. P. Diamandis, Department of
Laboratory Medicine and Pathobiology at the University of Toronto, Toronto, Ontario. These
antibodies included rabbit polyclonal antibodies produced in mammalian stable cell lines, against
KLKs (KLK 7,8,10,11,14). The production of these KLK antibodies has been fully described by
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Diamandis et al. (Reference: Diamandis EP, et al. Pathology and Genetics of human kallikrein 6
(zyme/protease M/neurosin) and preliminary clinical applications. Clin Biochem. 2000;33:36975).
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Table 2.6.1: IHC samples
Specific KLK
Antibody
KLK7
KLK8
KLK 10
KLK 11
KLK 14

Sample #

Sample #

LOW LEVEL
6
6, 16
11
6
6

HIGH LEVEL
16
11
6, 10
11
11

Table 2.6.2.1: Positive Controls for Selected KLK Antibodies
Kallikrein antibody

Positive control

KLK 7

Adenoid cystic carcinoma

KLK 8

Skin

KLK 10

Normal salivary gland

KLK 11

Prostate

KLK 14

Skin

Table 2.6.2.2: Specific KLK antibody dilutions
Kallikrein Antibody

Antibody titre

Incubation

KLK 7

1:3200

Overnight at 4°C

KLK 8

1:100

Overnight at 4°C

KLK 10

1:1200

Overnight at 4°C

KLK 11

1:2400

Overnight at 4°C

KLK 14

1:3200

Overnight at 4°C
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2.6.4 Paraffin Sections
Formalin-fixed, paraffin-embedded PLGA tissue blocks were obtained. A microtome
(Microm HM 325, GMI Inc., Ramsey, MN, USA, SKU# 8243 30 1006) was used to prepare 5µm
thick serial sections, which were transferred to a water bath at 45°C, mounted on positively charged
microscopic slides and oven-dried overnight via incubation at 37°C. The following solution
immersions were completed to de-paraffinize and rehydrate the tissue sections: 3 changes of
xylene for 5 minutes, 100% ethanol for 3 minutes, 95% ethanol for 3 minutes, 70% ethanol for 1
minute, 100% distilled water for 3 minutes. Quenching was completed with 3% hydrogen peroxide
in methanol for 5 minutes, followed by rinsing in 100% distilled water, and PBS.
2.6.5 Staining procedure
The prepared tissue sections for each PLGA sample were subjected to antigen retrieval.
Slides were placed in citrate buffer (pH 6.0), at 125 °C in a de-cloaking chamber. The slides were
rinsed in water and PBS for 5 minutes. We blocked the slides using 10% horse serum at room
temperature for 30 minutes. After blocking, appropriately diluted primary antibodies for the KLK
were added to the slides according to conditions outlined in Table 3.7.2.2. Detection was
performed ImmPRESS ® Reagent Kit (Vector Laboratories, Burlingame, CA, Catalogue No: MP7401). The slides were then stained with 3,3’-diaminobenzidine tetrahydrochloride (DAB
Peroxidase Substrate Kit, Vector Laboratories, Burlingame, CA, Catalogue No: SK-4100) for 10
minutes at room temperature. Slides were then counterstained with hematoxylin, dehydrated, and
mounted using Cytoseal® (VWR, Mississauga, Ontario, Catalogue No: 48212-154).
2.7 Data collection and statistical analysis for immunohistochemistry
2.7.1 Scoring Criteria
The KLK staining of each PLGA sample was viewed under brightfield microscopy and
assessed semi-quantitatively, using a well-documented method, as described by Allred et al.[76,
87]. This was completed by an Oral Pathologist and the graduate student author. A proportion
score and intensity score, displayed in Tables 3.7.1.1 and 3.7.1.2 respectively, was used to evaluate
each stained tissue sample. The proportion score indicates the estimated fraction of positive
staining tumour cell nuclei (0-5), while the intensity score evaluates the average staining intensity
of tumour cell nuclei. An overall staining score (OSS) was then generated, ranging from 0-8, for
46

each sample. A negative score is represented as 0, and positive scores range from 2-8[87]. Figure
2.7.1.1 demonstrates a pictorial interpretation of the Allred scoring system[88].
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Table 2.7.1.1: Proportion score for estimated fraction of immunoreactive tumour cells
Score

Proportion of cells stained

0

0

1

<1/100

2

1/100-1/10

3

1/10-1/3

4

1/3-2/3

5

>2/3

Table 2.7.1.2: Intensity score for tumour cells
Score

Staining Intensity

0

None

1

Weak

2

Intermediate

3

Strong
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Figure 2.7.1.1 Diagrammatic Representation of Interpretation of Allred Scores. This figure
was originally published in Journal of Pakistan Medical Association. Qureshi, A. and Pervez, S.
Allred scoring for ER reporting and its impact in clearly distinguishing ER negative from ER
positive breast cancers. 60:350; 2010. The figure is being reproduced for educational purposes
only and not for any commercial use. Figure is included in the M. Sc. Dissertation with attribution.
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Chapter 3
3.0 Results
3.1 RNA isolation
The RNA isolated from PLGA samples is shown in Table 4.1.1. In samples 14, 18, and 19,
the RNA amount was not detectable. The average amount of RNA obtained from the remaining
16 samples was 0.297 µg/mL. Equal amount of RNA was used to synthesize cDNA for qPCR
studies.
3.2 Expression of KLKs in cDNA of PLGA
The expression of KLK mRNA in samples of PLGA was examined for KLK1-15. All
samples of PLGA tissue demonstrated expression of at least four KLKs and as many as thirteen
KLKs. The percentages of PLGA tissues exhibiting each KLK are listed in Table 4.2.1. KLK7 was
the least likely to be expressed in the samples, detectable in just 18.8% cases. KLK6, 11, and 13
were present in 25% cases. Whereas, KLK1 and 2 were most commonly expressed.
3.3 Expression of KLKs in PLGA compared to normal salivary gland tissue (NSGT)
The mean expression of each KLK was calculated for all PLGA samples. Figures 4.3.14.3.15 demonstrate KLK mRNA expression in PLGA tissues compared to NSGT. The data was
tested for normality and statistical significance was determined using Mann Whitney U Test. For
each KLK, the mean mRNA expression obtained from biological replicates was found to be greater
in the PLGA samples compared to NSGT. This was statistically significant for 1, 4, 10, 12, 15.
The relative fold change of mRNA expression for each KLK in PLGA versus NSGT is
demonstrated in Figure 4.3.16. to illustrate the overall profile.
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Table 3.1.1 RNA quantification by Qubit Fluorometer for each PLGA tissue sample.
Sample
Number
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19

RNA
µg/mL
0.091
0.121
0.075
0.072
0.214
0.898
0.139
0.065
0.322
0.244
1.04
0.238
0.520
too low
0.120
0.426
0.163
too low
too low
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Table 3.2.1 Percentages of PLGA cases with detectable KLK mRNA. These percentages are
generated by the number of case samples (out of 16 total) which demonstrated mRNA for each
KLK.
KLK

PLGA %

KLK1

87.5

KLK2

87.5

KLK3

62.5

KLK4

43.8

KLK5

68.8

KLK6

25

KLK7

18.8

KLK8

31.3

KLK9

50

KLK10

62.5

KLK11

25

KLK12

68.8

KLK13

25

KLK14

37.5

KLK15

37.5
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Figure 3.3.1: Mean value of KLK1 mRNA expression in PLGA vs NSGT. Statistical
significance determined by Mann Whitney U Test (p<0.05)

0.8

KLK1 mRNA

0.6

*

0.4

0.2

0
Normal

PLGA

Figure 3.3.2: Mean value of KLK2 mRNA expression in PLGA vs NSGT. Statistical
significance determined by Mann Whitney U Test (p<0.05)

0.8

KLK2 mRNA

0.6

0.4

0.2

0
Normal

PLGA
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Figure 3.3.3: Mean value of KLK3 mRNA expression in PLGA vs NSGT. Statistical
significance determined by Mann Whitney U Test (p<0.05)
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KLK3 mRNA

0.6

0.4

0.2

0
Normal

PLGA

Figure 3.3.4: Mean value of KLK4 mRNA expression in PLGA vs NSGT. Statistical
significance determined by Mann Whitney U Test (p<0.05)
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0
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Figure 3.3.5: Mean value of KLK5 mRNA expression in PLGA vs NSGT. Statistical
significance determined by Mann Whitney U Test (p<0.05)
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0
Normal
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Figure 3.3.6: Mean value of KLK6 mRNA expression in PLGA vs NSGT. Statistical
significance determined by Mann Whitney U Test (p<0.05)
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Figure 3.3.7: Mean value of KLK7 mRNA expression in PLGA vs NSGT. Statistical
significance determined by Mann Whitney U Test (p<0.05)
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Figure 3.3.8: Mean value of KLK8 mRNA expression in PLGA vs NSGT. Statistical
significance determined by Mann Whitney U Test (p<0.05)
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Figure 3.3.9: Mean value of KLK9 mRNA expression in PLGA vs NSGT. Statistical
significance determined by Mann Whitney U Test (p<0.05)
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Figure 3.3.10: Mean value of KLK10 mRNA expression in PLGA vs NSGT. Statistical
significance determined by Mann Whitney U Test (p<0.05)
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Figure 3.3.11: Mean value of KLK11 mRNA expression in PLGA vs NSGT. Statistical
significance determined by Mann Whitney U Test (p<0.05)
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Figure 3.3.12: Mean value of KLK12 mRNA expression in PLGA vs NSGT. Statistical
significance determined by Mann Whitney U Test (p<0.05)
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Figure 3.3.13: Mean value of KLK13 mRNA expression in PLGA vs NSGT. Statistical
significance determined by Mann Whitney U Test (p<0.05)
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Figure 3.3.14: Mean value of KLK14 mRNA expression in PLGA vs NSGT. Statistical
significance determined by Mann Whitney U Test (p<0.05)
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Figure 3.3.15: Mean value of KLK15 mRNA expression in PLGA vs NSGT. Statistical
significance determined by Mann Whitney U Test (p<0.05)
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Figure 3.3.16: Relative fold increase of mRNA levels of KLK1-15 in PLGA tissue as
compared with normal salivary gland tissues. Statistical significance determined by Mann
Whitney U Test (p<0.05; illustrated by asterisk). Standard error of mean (SEM) is demarcated
by the error bars.
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Table 3.3.1 Calculated p-values, as determined by Mann Whitney U Test, for the
comparison of expression of KLK1-15 in PLGA tissues and NSGT.
KLK Gene

p-value

KLK1

0.00672

KLK2

0.82588

KLK3

0.59612

KLK4

0.03236

KLK5

0.238

KLK6

Sample number low

KLK7

Sample number low

KLK8

0.15854

KLK9

0.71138

KLK10

0.00804

KLK11

Sample number low

KLK12

0.0536

KLK13

Sample number low

KLK14

0.88076

KLK15

0.00386
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3.4 Immunohistochemical staining results
Representative immunohistochemical staining images are shown in Figures 4.4.1-4.4.5 of
PLGA tissue samples stained for specific KLKs. For each KLK antibody, at least one PLGA
sample demonstrating relatively low mRNA expression and one PLGA sample demonstrating
relatively high mRNA expression are presented. Negative controls for each PLGA sample were
completed with addition of primary antibody and images and are displayed in Figure 4.4.6.
Furthermore, positive control tissues were stained for their respective KLK antibody and are
presented in Figure 4.4.7. ACC was used as a positive control for a KLK7, skin was used as a
positive control for KLK8 and KLK14, NSGT was used as a positive control for KLK10, and
prostate tissue was used as a positive control for KLK11.
The IHC staining results are outlined in Table 4.4.1. Samples demonstrating relatively high
KLK expression exhibited staining of all tumour cells (grade 5) and the intensity grade of the stains
varied from 1-3. Samples demonstrating relative low KLK expression exhibited staining of most
tumour cells (grades 4-5) and the intensity grade of the stains varied from <1-3. With respect to
localization of a specific KLK, the samples with higher mRNA expression demonstrated
equivalent or increased grade of immunohistochemical staining, as compared to samples with
lower mRNA expression. Most of the KLK immunoreactivity in PLGA samples was primarily
cytoplasmic, with some exceptions. Nuclear staining pattern was seen with KLK7 (samples 6&16),
KLK11 (samples 6&11), and KLK14 (samples 6&11). KLK10 exhibited inflammatory cell
staining in sample 10, and epithelial cell staining in sample 11. All samples noted negative stromal
staining.
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Figure 3.4.1 Immunohistochemical localization of KLK7 in PLGA. Sample 6 (a) had relatively
low KLK7 mRNA expression on PCR, while Sample 16 (b) had relatively high KLK7 mRNA
expression on PCR. {images taken at 200x magnification; blue = hematoxylin nuclear stain;
brown = diaminobenzidine/DAB chromogen}.

(a)

(b)
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Figure 3.4.2 Immunohistochemical localization of KLK8 in PLGA. Samples 6 and 16 (a)&(b)
had relatively low KLK8 mRNA expression on PCR, while Sample 11 (c) had relatively high KLK8
mRNA expression on PCR. {images taken at 200x magnification; blue = hematoxylin nuclear
stain; brown = diaminobenzidine/DAB chromogen}.

(a)

(b)

(c)
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Figure 3.4.3 Immunohistochemical localization of KLK10 in PLGA. Sample 11 (a) had
relatively low KLK10 mRNA expression on PCR, while Samples 6 (b) and 10 (c) had relatively
high KLK10 mRNA expression on PCR. {images taken at 200x magnification; blue = hematoxylin
nuclear stain; brown = diaminobenzidine/DAB chromogen}.

(a)

(b)

(c)
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Figure 3.4.4 Immunohistochemical localization of KLK11 in PLGA. Sample 6 (a) had
relatively low KLK11 mRNA expression on PCR, while Sample 11 (b) had relatively high KLK11
mRNA expression on PCR. {images taken at 200x magnification; blue = hematoxylin nuclear
stain; brown = diaminobenzidine/DAB chromogen}.

(a)

(b)
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Figure 3.4.5 Immunohistochemical localization of KLK14 in PLGA. Sample 6 (a) had
relatively low KLK14 mRNA expression on PCR, while Sample 11 (b) had relatively high KLK14
mRNA expression on PCR. {images taken at 200x magnification; blue = hematoxylin nuclear
stain; brown = diaminobenzidine/DAB chromogen}.

(a)

(b)
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Figure 3.4.6 Negative controls for KLK staining. Below (a)-(d) demonstrate IHC on Samples 6,
10, 11, and 16 respectively, completed without KLK (primary) antibody {images taken at 200x
magnification; blue = hematoxylin nuclear stain; brown = diaminobenzidine/DAB chromogen}.

(a)

(b)

(c)

(d)
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Figure 3.4.7 Immunohistochemical localization of KLK in controls. Representative
immunohistochemical stain images of tissues with known KLK expression are shown. ACC (a) was
used as a KLK7 control, Skin (b)&(e) was used as a control for KLK8 and 14 respectively, NSGT
(c) was used as a KLK10 control, and prostate (d) was used as a KLK11 control {images taken at
200x magnification; blue = hematoxylin nuclear stain; brown = diaminobenzidine/DAB
chromogen}.

(a)

(b)

(c)

(d)

69

(e)
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Table 3.4.1 Immunohistochemistry stain results. IHC proportionality grade, intensity and
overall score are recorded below, along with specific staining characteristics seen in each
sample.
Antibody

Sample
#

KLK7

6

Level
of
mRNA
low

IHC

IHC

IHC

Stromal

Grade

Intensity

Score

Stain

5

2

7

-

OTHER

Cytoplasmic and
nuclear staining

KLK7

16

high

5

2

7

-

Cytoplasmic and
nuclear staining

KLK8

6

low

4

1

5

-

Primarily
cytoplasmic
staining

KLK8

16

low

4

1

5

-

Primarily
cytoplasmic
staining

KLK8

11

high

5

1

6

-

All cytoplasmic
staining

KLK10

11

low

5

1

6

-

Epithelial positive
cells

KLK10

6

high

5

1

6

-

All cytoplasmic
staining

KLK10

10

high

5

1

6

-

All cytoplasmic
staining;
inflammatory
cells staining
positively

KLK11

6

low

5

2

7

-

Primary
cytoplasmic
staining; many
nuclei staining

KLK11

11

high

5

3

8

-

Primary
cytoplasmic
staining; some
positive and
negative nuclei
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KLK14

6

low

5

3

8

-

Primarily
cytoplasmic
staining; some
nuclei staining

KLK14

11

high

5

3

8

-

Primarily
cytoplasmic
staining; much
nuclear staining

Table 3.5.1 Summary of PCR and IHC results
Total PLGA

Case 6

Case 10

Case 11

Case 16

Samples

KLK7

average
level of
mRNA
0.45908

Median
value of
mRNA
0.37725

mRNA

IHC

mRNA

score
Low,

IHC

mRNA

score

IHC
score

7

0.25982

0.09694

Low,

0.27191

0.12312

High,

5

High,

0.51035

0.44622

Low,

6

High,
0.138793

7

0.18320

0.02862

Low,

6

Low,

6
8

1.0
8

High,

0.02862

1.0
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Low,
0.1049704

0.048942
High,

0.0
KLK14

7

1.0

0.225234
KLK11

7

0.377251

0.0969368
KLK10

IHC
score

High,

0.0
KLK8

mRNA

8

5

3.5 PCR and IHC Correlation
The results from PCR KLK mRNA quantification and IHC staining were compared and
the findings are summarized in Table 4.5.1.
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Chapter 4
4.0 Discussion
4.1 Increased mRNA levels of KLKs in PLGA
Our study confirms the hypothesis that KLKs are aberrantly expression in PLGA. Through
qPCR, we demonstrated that KLK mRNA levels are increased in PLGA compared to normal
salivary gland tissues. This upregulation was statistically significant for KLK1, KLK4, KLK10,
KLK12, and KLK15, as determined by Mann Whitney U Test (p<0.05). We also noted greater
variability in mRNA levels of KLK6, KLK7, KLK11 and KLK13; indicative of lower percentages
of samples expressing these KLKs: 25%, 18.8%, 25% and 25%, respectively.
4.2 IHC demonstrates PLGA tumour cell-specific staining pattern
To address whether KLK upregulation in PLGA samples was specific to the tumour cells,
we performed immunohistochemistry. For these studies, we randomly selected patient samples
showing relatively high and low mRNA levels (arbitrary) for KLK for which antibodies were
available. These KLKs included KLK7, KLK8, KLK10, KLK11, and KLK14. PLGA samples
were stained and evaluated, using a well-documented system[76]. Proportion scores for each
PLGA case stained with KLK antibody noted most tumour cells were staining positive (proportion
score 5), save for two samples with KLK8 demonstrating scores of 4, indicating slightly less
percentage of tumour cells which were immunoreactive. Intensity scores varied between cases.
These results confirmed our hypothesis that tumour cells are the primary source of KLK mRNA.
4.3 KLK mRNA profile of PLGA vs ACC
Our laboratory has recently profiled ACC samples for KLK mRNA levels, providing us
with a unique opportunity to compare the profile to PLGA [84]. ACC samples exhibited
significantly lower levels of KLK1, KLK8, KLK11 and KLK14 compared to NSGT; the remaining
KLKs were expressed at levels comparable to that of NSGT[84]. In the present study, KLK1,
KLK4, KLK10, KLK12, and KLK15 were found to be significantly upregulated when compared
to NSGT. These differences, particularly KLK1, may be useful in distinguishing PLGA from ACC,
which can pose a diagnostic challenge due to their histomorphologic resemblance[14, 34].
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Microscopically, both PLGA and ACC exhibit diffusely invasive borders, solid and
cribriform growth patterns, and perineural invasion[35]. ACC is more common in major salivary
glands, which is a distinguishing feature versus PLGA’s predilection for the minor salivary glands;
smaller cell size with less cytoplasm and nuclear features may also differentiate ACC from
PLGA[6, 9]. Due to their prognostic distinctions, ACC having a worse prognosis and more
aggressive clinical course as compared to PLGA, misdiagnosis between these two tumours would
be an erroneous pitfall[9]. KLK1 mRNA was present in 73% of ACC samples studied by Kerr et
al., and in the present study, KLK1 mRNA was expressed in 87.5% of PLGA samples[84]. Given
KLK1 was found to be significantly downregulated in ACC and significantly upregulated in
PLGA, this difference may lend itself to establishing a diagnostic panel, differentiating these two
salivary gland tumours.
4.4 Analysis of IHC staining of KLKs in PLGA
Overall, each sample with a relatively higher expression of KLK mRNA stained
equivalently or with a higher IHC score than the samples which had relatively lower KLK mRNA
expression. For KLK7, sample 6 demonstrated no mRNA expression, and sample 16 showed
relatively higher expression; however, both samples had equivalent IHC scores of 7. Similarly, for
KLK10, sample 11 had relatively low mRNA expression in comparison to samples 6 and 10, yet
the IHC score for all samples was 6. Furthermore, for KLK14, sample 6 had relatively low mRNA
expression in comparison to sample 11; IHC scores for both samples were 8. A small increase was
seen between samples for KLK11, with sample 6 demonstrating undetectable mRNA and an IHC
score of 7, while sample 11 having relatively higher mRNA expression and an IHC score of 8. The
most significant difference was seen with KLK8; sample 6 and sample 16 demonstrated relatively
lower mRNA levels and had IHC scores of 5, while sample 11 had relatively high mRNA and an
IHC score of 7.
Additional IHC staining results note that all samples demonstrated negative stromal
staining. Most samples exhibited primarily cytoplasmic staining for KLK. Nuclear staining was
seen for KLK7, KLK11 and KLK14. KLK10 demonstrated positive epithelial cell staining in
sample 11, while inflammatory cells stained positive for KLK10 in sample 10. Nuclear staining
with KLK7 in PLGA mirrors previous IHC results from PA, ACC, and MEC samples from our
laboratory[67].
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It is currently not clear as to why a sample with no demonstrable KLK mRNA on PCR
would stain positively for KLK protein. There could be a number of factors involved. For example,
immunoreactivity may represent sequestered protein rather than tumour-expressed protein. The
reactivity may also suggest high endogenous peroxidase activity in the PLGA specimens;
although, this may usually be confined to red and white blood cells[89]. Furthermore, this could
be attributed to nonspecific staining of the PLGA tissue samples. Tissue handling, including
fixative exposure and tissue desiccation may also contribute to non-specific staining.
The no to minimal differences in IHC scores between samples with low and high mRNA
expression may be explained by a number of postulations. PCR determines the amount of mRNA,
which may not perfectly correlate with the amount of protein assessed by IHC. Tumour cells may
be increasing mRNA stability which may lead to higher levels of transcripts. It is also possible that
since KLKs are secreted proteases, the rate of secretion may outpace translation. However, these
interesting avenues need further testing.
4.5 IHC staining of KLKs in salivary gland neoplasia
Darling et al., and Hashem et al. have completed significant work on KLK IHC staining
profiles of salivary gland neoplasia, as well as NSGT, including most of the KLKs used in this
study (KLK7, 8, 10 and 14). Hashem et al. noted KLK7 was significantly overexpressed in PA
and ACC (OSS 7.0 and 7.5 respectively), when compared to NSGT (OSS 6.5)[67]. Furthermore,
MEC (OSS 6.33) was not significantly different from NSGT. The PLGA cases in this study,
whether they had relatively low or higher mRNA expression, both had OSS of 7.0, which we can
extrapolate as significantly increased as compared to NSGT. In previous work by Darling et al.,
KLK8 was shown to be expressed in NSGT (OSS 7.0), and to demonstrate equal or increased OSS
in most malignancies: ACC (OSS 7.0+/-1.4), PLGA (OSS 6.9+/-0.5), ACI (OSS 7.0+/-0.8), ANOS
(OSS 7.6+/-0.7), and MEC (OSS 7.5+/-0.5)[54]. In the present study, OSS in relative lowexpressing KLK8 mRNA samples was 5, and in relatively higher expressing KLK8 mRNA
samples was 7, which is reasonably consistent with previous work. Darling et al. also described
KLK10 as found in NSGT (OSS 6.0), and no significant differences in KLK10 expression were
seen in malignancy: ACC (OSS 5.8), MEC (OSS 6.3)[55]. PLGA was not investigated in Darling
et al.’s study; however, in the present study, the OSS for KLK10 of our PLGA samples were
consistent with the other salivary gland malignancies studied (OSS 6 for all three cases). Hashem
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et al. noted KLK14 was present in NSGT (OSS 6.5), and that, while KLK14 was upregulated in
PA (OSS 7.25), there was no significant differences seen in salivary gland malignancies: MEC
(OSS 6.14), ACC (OSS 6.8)[55, 75]. KLK14 stains in our PLGA samples demonstrated OSS of 8,
despite differences in mRNA levels. Taken together, KLK14 may be recognized as over-expressed
in PLGA. Darling et al. noted KLK7, 10 and 14 appeared to be correlated in their expression in
ACC, all demonstrating no significant difference from NSGT. This same correlation does not seem
evident in our staining of PLGA; KLK7 and 14 show similar IHC profiles, but KLK10 shows
lower staining scores.
Additional IHC include nuclear staining seen with KLK7, KLK11 and KLK14. This could
suggest a role for these specific KLKs in transcription. Moreover, we could extrapolate that in
PLGA tumours, specific KLKs are active at the nuclear level to aberrantly regulate transcription,
leading to tumour pathogenic behaviour. Inflammatory cell staining was observed with KLK10,
which could demonstrate its involvement with an inflammatory process, contributing to malignant
features in the PLGA tumour.
In our experiment, we did not compare NSGT and PLGA staining, as we were interested
in correlated data from PCR (mRNA expression levels) with IHC, look to elucidate tumour specific
staining. However, by review previous works that have used the same IHC protocol and staining
scoring systems, this present study has added value to further characterizing KLK IHC staining
profiles in salivary gland neoplasia.
4.6 Study Limitations
A limitation to this experimental design is that we are unable to detect whether the KLK
protein is indeed active, we are only able to localize the protein. It is well established that KLKs
go through an extensive processing in order to be activated; this occurs through the “KLK
Activome”[60]. KLK genes are transcribed into a pre-pro-enzyme, which goes on to be
proteolytically processed into an inactive pro-KLK, which become secreted by cleaving their
amino terminal signal peptide[57]. Lastly, the pro-KLK is activated into a mature peptidase
extracellularly, by the cleavage of the amino terminal propeptide[51, 60]. This cleavage may be
done by the KLK itself, a different KLK, or a different protease[57, 63]. To determine the amount
of active KLK peptidases, one may consider measuring for the peptidase that leads to the final
activation cleavage process.
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Another limitation to the study design was the decision to utilize the entire tissue 3x10µm
tissue curls from the PLGA tissue samples, rather than selecting out for tumour tissue only.
Therefore, in addition to tumour cells, stromal cells and normal salivary gland tissue were
undeniably used in the experimentations, and this may have introduced a source of variability into
the results.
An additional limitation to the experimental design was the PLGA tissue samples coming
from FFPE, stored in archives over a range of years (1987-2013). There has been suggestion that
perhaps the length of storage of FFPE has effect on extracting macromolecules; however, in 2013,
Kokkat, et al., demonstrated no significant difference between macromolecules extracted from
FFPE blocks stored from a decade in comparison to current year blocks[90]. Some of our tissue
samples were stored greater than 12 years, and perhaps this affected our results and could account
for lack of specific KLK expression in our PLGA tissue samples. RNA does degrade over its
storage time; however, partially degraded samples may still be used in downstream experiments,
such as PCR[90]. Moreover, cross-linking as a result of the fixation process affects RNA
extraction, but the molecules remain recoverable, in fragmented forms, which are useable for
analysis, including determining mRNA expression[91]. It could be postulated that using fresh
frozen tissue samples of PLGA tumour would yield more high quality nucleic acids, and this could
have altered our results[91].
A limitation to be addressed is that the RT-PCR experiments carried out on NSGT samples
were completed by our group prior to completing RT-PCR on the PLGA samples used in our study.
These two data sets were compared, despite being run at different times. A criticism of this would
be that these data sets do not represent experiments run under the same conditions, as there can be
day to day changes in fluorescence. As a means to combat this, good PCR practice is maintained
with ensuring the housekeeping gene (β-actin) is 1-3 cycle thresholds of the normal. Repeating
RT-PCR with both samples at the same interval may be of benefit and eliminate this weakness in
our study.
Another limitation to our study includes KLK antibody availability, as the only antibodies
accessible for this experiment were KLK7, KLK8, KLK10, KLK11, and KLK14. Unfortunately,
all of these selected KLKs, except KLK10, are represented in the PLGA samples at low
percentages. For example, KLK7 was only expressed in 18.8% of PLGA samples. The exception
was KLK10, shown to be expressed in 62.5% of PLGA samples.
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Also, we chose to select representative PLGA samples for IHC, one with relatively higher
mRNA expression for a specific KLK, and one for relatively lower mRNA expression for a specific
KLK. This was done to address our aim of whether or not the increased expression of KLK mRNA
was tumour specific. To further support our finding of IHC scores being equivalent or higher in
those samples demonstrating relatively higher KLK mRNA as compared to those with relatively
lower KLK mRNA expression, all of our PLGA tissue samples could have been stained with the
available KLK antibodies.
Lastly, a limitation to our study includes our inability to designate a single KLK as a
biomarker for PLGA. As we note, KLKs are co-expressed in salivary gland neoplasia and we
suspect KLKs to be acting in proteolytic cascades[75]. Therefore, what holds more promise is
developing a pattern of KLK expression seen in PLGA, in comparison to different salivary gland
tumours.
4.7 Future directions
4.7.1 PLGA and activation of a kallikrein protein cascade
Gene expression of KLK1-15 was shown to be increased in PLGA tissue samples, relative
to NSGT. This may indicate that all of the KLKs are involved in a complex proteolytic cascade in
these salivary gland tumours, involving the transcription, translation and activation of each KLK.
A method of confirming this increased transcription of the KLK chromosome locus in PLGA could
involve examining the expression of the nearby genes for increased expression, mimicking that of
KLKs, in PLGA tissue samples. On the centromeric end, the KLK chromosome locus 19q13.4 is
flanked by testicular acid phosphatase (ACPT) and on the telomeric end, it is flanked by cancerassociated gene (CAG) and Siglec-9[50]. We could measure transcript levels of ACPT, CAG and
Siglec-9 in PLGA samples to test this notion. If and when it is established that there is an increase
of both KLK1-15 transcription and their flanking genes ACPT, CAG, Siglec-9, further
experiments could confirm the mechanisms of aberrant transcriptional activity of this region. This
could be achieved by investigating epigenetic alterations in PLGA tissue samples. Genomic
imprinting is an epigenetic process, which may include DNA methylation, histone modification,
and/or chromatin folding[92]. Imprinted genes are thought to occur in clusters and may have
associations with signalling pathways[93]. Genomic imprinting is known to contribute to various
human diseases, including Prader-Willi and Angelman’s syndrome; it is also thought to be
79

associated with the development and progression of malignancies[94]. Specifically, DNA
methylation is often associated with shutting a gene “off” and therefore, DNA hypomethylation
leads to an aberrant increase in gene transcription, thought to be implicated in cancer development
and progression[94]. Methylation assays could be utilized for the KLK chromosome locus
19q13.4, and surrounding regions, in PLGA samples[92]. Results of DNA hypomethylation would
indicate increased transcription of this locus in the development of PLGA tumours. Taken together,
this increased expression of the KLK chromosome locus and surrounding genes, with epigenetic
modifications to promote increased transcription, would support an active proteolytic cascade
involving KLK1-15 in PLGA tumours.
4.7.2 KLK upregulation and PRDK1 Hotspot Mutation in PLGA
PRKD1 is a gene that encodes a kinase, which has been implicated in a whole host of
malignant processes, including: colorectal, breast, esophageal, laryngeal, and other cancers[26, 27,
37]. In 2014, Weinreb et al. identified a PRDK1 hotspot mutation encoding p.Glu710Asp in
PLGA[27]. Upon examining their tumour bank, they found this hotspot mutation was present in
72.9% of cases[27]. Subsequently, the group concluded the PRDK1 mutation conferred a
neoplastic advantage to the PLGA tumour cells, as there was a significant increase in metastaticfree survival time in those with the mutation[27]. Given that PLGA is primarily indolent in nature,
with a low incidence of distant metastasis, this may speak to the nature of the malignancy itself,
rather than the hotspot mutation[11].
It would be of value to examine the PLGA samples from our study for the PRDK1 hotspot
mutation. This could be done by sequencing the PLGA samples, obtaining PRDK1 primers and
completing PCR amplification to localize for the hotspot mutation. Subsequently, this could then
be compared to our KLK data, examining the level of mRNA expression of particular KLKs in
each sample of PLGA having the hotspot mutation. Taken together, we would expect the samples
that have significant increased expression of KLKs would also express the PRDK1 hotspot
mutation.
4.7.3 PLGA cell lines, KLK overexpression and knockdown
To better elucidate the function of KLKs in PLGA, it would be useful to study the effect
of their activity or lack thereof on cancer cells. Previous studies have investigated the functional
significance of select KLKs in cancer cell lines. In 1998, Goyal et al. transfected KLK10-negative
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breast tumour cell lines with KLK10, and injected the cells in nude mice. They found that KLK10
overexpression inhibited tumour growth suggesting a tumour suppression role of KLK10 in breast
cancer[95]. More recently, Hu et al. performed a similar study in prostate cancer cells and also
showed that KLK10 conferred a tumour suppression role [96].
To our knowledge, KLK expression, and the resultant behaviour, has not been examined
in PLGA cell lines. When examining the consequences of PRDK1 mutation in cell behaviour,
Weinreb et al. used non-malignant breast epithelial cell lines, as PLGA cell lines and nonmalignant minor salivary gland cell models were not available[27]. It would be ideal to have an
established cell line from PLGA tumours; however, should this not be possible, there would be
value in examining cell behaviour in non-malignant breast epithelial cell lines with modulated
KLK expression. From the results of our study, it would be reasonable to examine either KLK1,
4, 10, 12, or 15, as they were statistically upregulated, when compared to NSGT. An expression
vector, for example coding for KLK1, or an empty vector could be transfected into cells, and
subsequent in vitro cell migration and invasion assays and cell proliferation assays would then be
performed to examine cell behaviour. Cells expressing KLK1 and KLK1 knockdown cells would
be compared. In addition, cells with modulated KLK may be injected in nude mice and
characteristics such as tumour growth, invasion and metastasis would be examined and compared.
A functional study such as this design could provide useful information for tumour
characterization, prognosis, clinical behaviour, and potentially lead to therapeutic targets[96].
4.7.4 Gender role in PLGA
PLGA more commonly occur in females, with a female-to-male ratio of 2.15:1[11, 19]. In
our study, we presented 19 cases of PLGA, 13 of which were found in women, yielding an above
average percentage of female patients. Given our results of increased expression of KLKs in
PLGA, it is interesting to postulate why this gender over-representation may be and if this
contributes to our overall results. It seems unclear as to why women are more likely than men to
get PLGA; however, a reasonable thought could be the involvement of hormones in the regulation
of tumour cells. Additionally, it would be useful to retrospectively examine the clinical features of
each tumour sample. For example, determining if recurrences were seen more with female or male
patients, or if clinical behaviour seemed to be gender specific. Unfortunately, with such a small
sample size of 19, clinical significance would not be obtainable. Perhaps a multi-centre
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retrospective analysis of patients with PLGA and the role of gender on tumour characteristics
would be a useful task.
4.7.5 KLK as biomarkers in PLGA
We note a limitation to our study was the inability to demonstrate a single KLK as a
biomarker for PLGA; however, we have added to the KLK expression profile of PLGA, with hopes
of further developing a recognizable KLK pattern in PLGA, when compared to other salivary gland
neoplasia. A way to add information to KLK pattern in PLGA would be to examine released KLK
in bodily secretions (e.g. saliva) in patients with known PLGA. FFPE tissue from the patient’s
tumour would be used to examine KLK mRNA expression; however, this would then be compared
released KLK protein in saliva, as determined by ELISA, to note any significant differences. As
described in previous sections, biomarkers have been categorized as pharmacodynamics,
prognostic, and predictive. While it would be an aim of future directions to develop an efficacious
biomarker for PLGA which is diagnostic, it would also be valuable to have a prognostic biomarker,
which could indicate the likely clinical course of disease the patient would endure if not treated,
and/or the likely outcome of disease apart from treatment selection. A biomarker for PLGA would
be unlikely to be pharmacodynamic and/or predictive, given the use of drug therapy has no
demonstrable benefit at present. Again, we anticipate that multiple KLKs are involved in
functional protein cascades and this additional experimentation would aid in further developing
the KLK profile in salivary gland pathology.
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Chapter 5
5.0 Conclusion
This study examined the expression of human tissue kallikreins in PLGA. Quantification
of KLK1-15 mRNA in this tumour has not been reported to date. Through RT-qPCR, we
demonstrated that KLK1, KLK4, KLK10, KLK12, and KLK15 expression is upregulated in
PLGA. The average levels of KLK1, KLK4, KLK10, KLK12, and KLK15 mRNA expressed in
PLGA tissue samples were increased relative to NSGT. Immunohistochemistry was carried out on
PLGA samples showing relatively lower or higher mRNA KLK expression, and showed tumour
cell-specific immunoreactivity.
In conclusion, we believe KLK upregulation in PLGA indicates the involvement of a
complex proteolytic cascade, and may involve KLK 1, KLK4, KLK10, KLK12, and KLK15. We
suspect this upregulation of KLK activity may be involved in regulating malignant processes in
PLGA, and thus implicated in determining its clinical characteristics, including indolent behaviour
and infrequent metastatic spread. Furthermore, the results of this study significantly add to the
KLK profile of salivary gland neoplasia, at the mRNA and protein level. Importantly, when
combining the resultant KLK profile in PLGA with the recently elucidated KLK profile in ACC,
the resultant differences may render a diagnostic panel useful in differentiating between the
malignancies.
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